West Pharmaceutical Services (WST) 10-Q 29 Oct 19 2019 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information	9 Months Ended
	Sep. 30, 2019shares
Document and Entity Information [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2019
Document Transition Report	false
Entity File Number	1-8036
Entity Registrant Name	WEST PHARMACEUTICAL SERVICES, INC.
Entity Incorporation, State or Country Code	PA
Entity Tax Identification Number	23-1210010
Entity Address, Address Line One	530 Herman O. West Drive,
Entity Address, City or Town	Exton,
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19341-0645
City Area Code	610
Local Phone Number	594-2900
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of each class	Common Stock, par value $0.25 per share
Trading Symbol	WST
Security Exchange Name	NYSE
Entity Central Index Key	0000105770
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Amendment Flag	false
Entity Common Stock, Shares Outstanding	73,990,675

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Statement [Abstract]
Net sales	$ 456.1	$ 431.7	$ 1,369.3	$ 1,294.9
Cost of goods and services sold	308.3	296.1	916.8	882.7
Gross profit	147.8	135.6	452.5	412.2
Research and development	9.3	10.1	28.7	30.5
Selling, general and administrative expenses	64.8	64.9	203.7	203.2
Other expense (income) (Note 15)	6.4	(0.2)	1.6	4
Operating profit	67.3	60.8	218.5	174.5
Interest expense	2.1	2	6.4	6.1
Interest income	(1)	(0.5)	(2.5)	(1.4)
Other nonoperating expense (income)	(1.3)	1.8	(0.2)	5.1
Income before income taxes	64.9	61.1	214.4	174.9
Income tax expense	10.9	8	42.5	26.5
Equity in net income of affiliated companies	(2.3)	(2.1)	(5.9)	(6.5)
Net income	$ 56.3	$ 55.2	$ 177.8	$ 154.9
Net income per share:
Basic (in dollars per share)	$ 0.76	$ 0.75	$ 2.40	$ 2.10
Diluted (in dollars per share)	$ 0.75	$ 0.73	$ 2.36	$ 2.05
Weighted average shares outstanding:
Basic (in shares)	74	73.9	73.9	73.9
Diluted (in shares)	75.5	75.7	75.3	75.4

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 56.3	$ 55.2	$ 177.8	$ 154.9
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments	(23.8)	(9.5)	(20.1)	(39.1)
Defined benefit pension and other postretirement plan adjustments, net of tax of $0.7, $0, $0.7 and $0.1, respectively	2.4	(0.2)	2.2	0.1
Net gain (loss) on derivatives, net of tax of $1.5, $(0.1), $0.7, and $1.0, respectively	3.2	(0.4)	1.7	2.5
Other comprehensive loss, net of tax	(18.2)	(10.1)	(16.2)	(36.5)
Comprehensive income	$ 38.1	$ 45.1	$ 161.6	$ 118.4

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Statement of Comprehensive Income [Abstract]
Defined benefit pension and other postretirement plan adjustments, tax	$ 0.7	$ 0	$ 0.7	$ 0.1
Net gain (loss) on derivatives, tax	$ 1.5	$ (0.1)	$ 0.7	$ 1

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 396	$ 337.4
Accounts receivable, net	316.1	288.2
Inventories	230.4	214.5
Other current assets	61.6	54.3
Total current assets	1,004.1	894.4
Property, plant and equipment	1,779.8	1,752.7
Less: accumulated depreciation and amortization	967.7	930.7
Property, plant and equipment, net	812.1	822
Operating lease right-of-use assets	71.3	0
Investments in affiliated companies	97.4	91.2
Goodwill	106.6	105.8
Deferred income taxes	33.8	24.7
Intangible assets, net	28.7	20.3
Other noncurrent assets	20	20.5
Total Assets	2,174	1,978.9
Current liabilities:
Notes payable and other current debt	0	0.1
Accounts payable	145.3	130.4
Pension and other postretirement benefits	2.2	2.3
Accrued salaries, wages and benefits	72.6	64.5
Income taxes payable	19.1	9.8
Operating lease liabilities, current	9.8	0
Other current liabilities	86	76.6
Total current liabilities	335	283.7
Long-term debt	195.1	196
Deferred income taxes	10.3	13.1
Pension and other postretirement benefits	46.8	56.2
Operating lease liabilities, noncurrent	63.5	0
Other long-term liabilities	35.7	33.6
Total Liabilities	686.4	582.6
Commitments and contingencies (Note 15)
Equity:
Preferred stock, 3.0 million shares authorized; 0 shares issued and outstanding	0	0
Common stock, par value $0.25 per share; 100.0 million shares authorized; shares issued: 75.3 million and 75.3 million; shares outstanding: 74.0 million and 74.1 million	18.8	18.8
Capital in excess of par value	268.5	282
Retained earnings	1,497.3	1,353.4
Accumulated other comprehensive loss	(170.4)	(154.2)
Treasury stock, at cost (1.3 million and 1.2 million shares)	(126.6)	(103.7)
Total Equity	1,487.6	1,396.3
Total Liabilities and Equity	$ 2,174	$ 1,978.9

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - $ / shares shares in Millions	Sep. 30, 2019	Dec. 31, 2018
Balance Sheet Related Disclosures [Abstract]
Preferred stock, shares authorized (in shares)	3	3
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.25	$ 0.25
Common stock, shares authorized (in shares)	100	100
Common stock, shares issued (in shares)	75.3	75.3
Common stock, shares outstanding (in shares)	74	74.1
Treasury stock, at cost (in shares)	1.3	1.2

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Cash flows from operating activities:
Net income	$ 177.8	$ 154.9
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	74.6	76.1
Amortization	2.5	2
Stock-based compensation	18.8	14.7
Non-cash restructuring charges	1.6	0.8
Pension settlement charge	2.7	0
Contingent consideration payments in excess of acquisition-date liability	(0.3)	(0.5)
Other non-cash items, net	(0.6)	(4)
Changes in assets and liabilities	(16.3)	(28.6)
Net cash provided by operating activities	260.8	215.4
Cash flows from investing activities:
Capital expenditures	(88.8)	(74.7)
Acquisition of business	(18.9)	0
Other, net	0.3	2.5
Net cash used in investing activities	(107.4)	(72.2)
Cash flows from financing activities:
Borrowings under revolving credit agreements	28	0
Repayments under revolving credit agreements	(28)	0
Debt issuance costs	(0.9)	0
Dividend payments	(33.3)	(31)
Proceeds from stock-based compensation awards	25.5	25.7
Employee stock purchase plan contributions	4	3.6
Shares purchased under share repurchase programs	(83.1)	(70.8)
Net cash used in financing activities	(87.8)	(72.5)
Effect of exchange rates on cash	(7)	(9.3)
Net increase in cash and cash equivalents	58.6	61.4
Cash and cash equivalents at beginning of period	337.4	235.9
Cash and cash equivalents at end of period	$ 396	$ 297.3

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Summary of Significant Accounting Policies Basis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2019 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “ 2018 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year. In April 2019, we acquired the business of our distributor in South Korea for $18.9 million . As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million , $0.6 million , $2.6 million and $11.2 million , respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date. As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 15, Other Expense , to the consolidated financial statements in our 2018 Annual Report for further discussion.

New Accounting Standards

New Accounting Standards	9 Months Ended
	Sep. 30, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Standards	New Accounting Standards Recently Adopted Standards In August 2018, the SEC adopted a final release which would eliminate or modify certain disclosure requirements that are redundant, outdated, or duplicative of U.S. GAAP or other regulatory requirements. Among other changes, the amendments provide that disclosure requirements related to the analysis of shareholders’ equity are expanded for interim purposes. An analysis of the changes in each caption of shareholders’ equity presented in the balance sheet must be provided in a note or separate statement, as well as the amount of dividends per share for each class of shares. We provided this disclosure beginning in the first quarter of 2019. Please refer to Note 12, Shareholders ’ Equity . In June 2018, the Financial Accounting Standards Board (“FASB”) issued guidance which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2018, the FASB issued guidance to address a specific consequence of the Tax Cuts and Jobs Acts (the “2017 Tax Act”) by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis, but elected to not reclassify from accumulated other comprehensive income (loss) to retained earnings the stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. In August 2017, the FASB issued guidance which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases, Accounting Standards Codification (“ASC”) Topic 842 (“ASC 842”). This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. Please refer to Note 6, Leases , for additional information. Standards Issued Not Yet Adopted In April 2019, the FASB issued guidance which clarifies and improves areas of guidance related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity at each reporting date. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2019
Revenue [Abstract]
Revenue from Contract with Customer [Text Block]	Revenue The following table presents the approximate percentage of our net sales by market group: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Biologics 26 % 21 % 25 % 21 % Generics 20 % 21 % 20 % 21 % Pharma 30 % 34 % 31 % 35 % Contract-Manufactured Products 24 % 24 % 24 % 23 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended Nine Months Ended 2019 2018 2019 2018 High-Value Components 42 % 41 % 43 % 42 % Standard Packaging 28 % 31 % 29 % 32 % Delivery Devices 6 % 4 % 4 % 3 % Contract-Manufactured Products 24 % 24 % 24 % 23 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Americas 48 % 51 % 48 % 48 % Europe, Middle East, Africa 44 % 41 % 44 % 44 % Asia Pacific 8 % 8 % 8 % 8 % 100 % 100 % 100 % 100 % Contract Assets and Liabilities The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2018 $ 9.1 Contract assets, September 30, 2019 9.4 Change in contract assets - increase (decrease) $ 0.3 Deferred income, December 31, 2018 $ (33.4 ) Deferred income, September 30, 2019 (30.9 ) Change in deferred income - decrease (increase) $ 2.5 The decrease in deferred income during the nine months ended September 30, 2019 was primarily due to the recognition of revenue of $79.3 million , including $18.0 million of revenue that was included in deferred income at the beginning of the year, and $2.7 million in other adjustments, partially offset by additional cash payments of $79.5 million received in advance of satisfying future performance obligations. The majority of the performance obligations within our contracts are satisfied within one year or less. Performance obligations satisfied beyond one year include those relating to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose ® technology platform within a specific therapeutic area. As of September 30, 2019 , there was $5.9 million of unearned income related to this payment, of which $0.9 million was included in other current liabilities and $5.0 million was included in other long-term liabilities. The unearned income is being recognized as income on a straight-line basis over the remaining term of the agreement. The agreement does not include a future minimum purchase commitment from the customer. Supply Chain Financing We have entered into supply chain financing agreements with certain banks, pursuant to which we offer for sale certain accounts receivable to such banks from time to time, subject to the terms of the applicable agreements. These transactions result in a reduction in accounts receivable, as the agreements transfer effective control over, and credit risk related to, the receivables to the banks. These agreements do not allow for recourse in the event of uncollectibility, and we do not retain any interest in the underlying accounts receivable once sold. As of September 30, 2019 , we derecognized $7.9 million of accounts receivable under these agreements. Discount fees related to the sale of such accounts receivable on our condensed consolidated income statements for the nine months ended September 30, 2019 were not material. Voluntary Recall On January 24, 2019, we issued a voluntary recall of our Vial2Bag ® product line due to reports of potential unpredictable or variable dosing under certain conditions. Our fourth quarter 2018 results included an $11.3 million provision for product returns, recorded as a reduction of sales, partially offset by a reduction in cost of goods sold reflecting our inventory balance for these devices at December 31, 2018. During the three and nine months ended September 30, 2019 , we recorded a net adjustment of $0.9 million and a net provision of $4.9 million , respectively, for potential inventory returns from our customers and related in-house inventory, partially offset by a reduction in our provision for product returns. We continue to work to get the products back on the market.

Net Income Per Share

Net Income Per Share	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Net income $ 56.3 $ 55.2 $ 177.8 $ 154.9 Weighted average common shares outstanding 74.0 73.9 73.9 73.9 Dilutive effect of equity awards, based on the treasury stock method 1.5 1.8 1.4 1.5 Weighted average shares assuming dilution 75.5 75.7 75.3 75.4 During the three months ended September 30, 2019 and 2018 , there were 0.1 million and 0.1 million shares, respectively, from stock-based compensation plans not included in the computation of diluted net income per share because their impact was antidilutive. There were 0.3 million and 0.4 million antidilutive shares outstanding during the nine months ended September 30, 2019 and 2018 , respectively. In February 2019, we announced a share repurchase program for calendar-year 2019 authorizing the repurchase of up to 800,000 shares of our common stock from time to time on the open market or in privately-negotiated transactions as permitted under the Securities Exchange Act of 1934 Rule 10b-18. The number of shares repurchased and the timing of such transactions depended on a variety of factors, including market conditions. There were no shares purchased during the three months ended September 30, 2019 . During the nine months ended September 30, 2019 , we purchased 800,000 shares of our common stock under the now-completed program at a cost of $83.1 million , or an average price of $103.89 per share.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows: ($ in millions) September 30, December 31, Raw materials $ 99.2 $ 90.4 Work in process 38.3 42.2 Finished goods 92.9 81.9 $ 230.4 $ 214.5

Leases

Leases	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Leases of Lessee Disclosure [Text Block]	Leases Adoption of ASC 842 On January 1, 2019, we adopted ASC 842, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. As a result, we were not required to adjust our comparative period financial information for effects of ASC 842 or present the new required lease disclosures for periods prior to the date of adoption. As of September 30, 2019 , we had operating leases primarily related to land, buildings, and machinery and equipment, with lease terms through 2047. Certain of our operating leases include options to extend the lease term for up to five years , and certain of our operating leases include options to terminate the leases within one year. We had no finance leases as of September 30, 2019 . As a result of our adoption of ASC 842, we recorded operating lease right-of-use assets of $71.0 million and operating lease liabilities of $73.1 million for operating leases where we are the lessee in our condensed consolidated balance sheet as of January 1, 2019. The operating lease right-of-use assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The operating lease right-of-use assets are subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. The operating lease liabilities are initially measured at the present value of the unpaid lease payments at the lease commencement date. Judgments used in applying ASC 842 include determining: i) whether a contract is, or contains, a lease; ii) the discount rate to be used to discount the unpaid lease payments to present value; iii) the lease term; and iv) the lease payments. We determine if a contract is, or contains, a lease at contract inception. A lease exists when a contract conveys to the customer the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. The definition of a lease embodies two conditions: 1) there is an identified asset in the contract that is land or a depreciable asset (i.e., property, plant, and equipment); and 2) the customer has the right to control the use of the identified asset. ASC 842 requires a lessee to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As all of our operating leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. Our incremental borrowing rate for a lease is the rate of interest we would have to pay on a collateralized basis to borrow an amount equal to the lease payments under similar terms. The lease term for all of our operating leases includes the noncancellable period of the lease plus any additional periods covered by either a lessee option to extend (or not to terminate) the lease that the lessee is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Lease payments included in the measurement of the operating lease right-of-use assets and lease liabilities are comprised of fixed payments (including in-substance fixed payments), variable payments that depend on an index or rate, and the exercise price of a lessee option to purchase the underlying asset if the lessee is reasonably certain to exercise. The components of lease expense were as follows: ($ in millions) Three Months Ended Nine Months Ended Operating lease cost $ 3.4 $ 9.7 Short-term lease cost 0.1 0.5 Variable lease cost 0.8 2.3 Total lease cost $ 4.3 $ 12.5 Lease expense for the three and nine months ended September 30, 2018 was $3.3 million and $10.4 million , respectively. Supplemental information related to leases was as follows: ($ in millions) Three Months Ended Nine Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3.2 $ 9.4 Right-of-use assets obtained in exchange for new operating lease liabilities $ 0.3 $ 8.4 As of September 30, 2019 , the weighted average remaining lease term for operating leases was 11.8 years, and the weighted average discount rate was 3.76% . Maturities of lease liabilities as of September 30, 2019 were as follows: ($ in millions) Operating Year Leases 2019 (remaining three months) $ 3.4 2020 12.0 2021 10.2 2022 8.3 2023 7.7 Thereafter 48.1 89.7 Less: imputed lease interest (16.4 ) Total lease liabilities $ 73.3 Maturities of future minimum rental payments under non-cancelable operating leases as of December 31, 2018 were as follows: ($ in millions) Operating Year Leases 2019 $ 13.0 2020 10.5 2021 7.8 2022 6.9 2023 5.5 Thereafter 37.8 Total $ 81.5 Practical Expedients and Exemptions We have elected to adopt the leasing package of practical expedients, which allows us to not retroactively reassess: i) any expired or existing contracts containing leases under the new definition of a lease; ii) the lease classification for any expired or existing leases; and iii) initial direct costs for any expired or existing leases. We have also elected to adopt practical expedients around land easements, the combination of lease and non-lease components, and the portfolio approach relating to discount rates. These practical expedients were applied consistently to all leases. We have elected not to recognize operating lease right-of-use assets and operating lease liabilities for all short-term leases (leases with an initial lease term of 12 months or less). We recognize the lease payments associated with our short-term leases as an expense over the lease term.

Affiliated Companies

Affiliated Companies	9 Months Ended
	Sep. 30, 2019
Equity Method Investments and Joint Ventures [Abstract]
Affiliated Companies	Affiliated Companies At September 30, 2019 and December 31, 2018 , the aggregate carrying amount of our investment in affiliated companies that are accounted for under the equity method was $84.0 million and $77.8 million , respectively, and the aggregate carrying amount of our investment in affiliated companies that are not accounted for under the equity method was $13.4 million at both period-ends. We have elected to record these investments, for which fair value was not readily determinable, at cost, less impairment, adjusted for subsequent observable price changes. We test these investments for impairment whenever circumstances indicate that the carrying value of the investments may not be recoverable. Our purchases from, and royalty payments made to, affiliates totaled $33.0 million and $85.2 million , respectively, for the three and nine months ended September 30, 2019 , as compared to $16.3 million and $64.0 million , respectively, for the same periods in 2018. As of September 30, 2019 and December 31, 2018 , the payable balance due to affiliates was $24.3 million and $12.9 million , respectively. The majority of these transactions related to a distributorship agreement with Daikyo Seiko, Ltd. (“Daikyo”) that allows us to purchase and re-sell Daikyo products. Sales to affiliates were $2.2 million and $6.9 million , respectively, for the three and nine months ended September 30, 2019 , as compared to $3.0 million and $8.0 million , respectively, for the same periods in 2018. As of September 30, 2019 and December 31, 2018 , the receivable balance due from affiliates was $1.4 million and $1.6 million , respectively. Please refer to Note 6, Affiliated Companies , to the consolidated financial statements in our 2018 Annual Report for additional details.

Debt

Debt	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Debt	Debt The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2019 . ($ in millions) September 30, December 31, Note payable, due December 31, 2019 $ — $ 0.1 Credit Facility, due October 15, 2020 — 28.6 Credit Facility, due March 28, 2024 (0.875%) 27.6 — Series A notes, due July 5, 2022 (3.67%) 42.0 42.0 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 195.6 196.7 Less: unamortized debt issuance costs 0.5 0.6 Total debt 195.1 196.1 Less: current portion of long-term debt — 0.1 Long-term debt, net $ 195.1 $ 196.0 In March 2019, we entered into a new senior unsecured, multi-currency revolving credit facility agreement (the “Credit Agreement”) that replaced our prior revolving credit facility, which was scheduled to expire in October 2020. The Credit Agreement, which expires in March 2024, contains a senior unsecured, multi-currency revolving credit facility (the “Credit Facility”) of $300.0 million , with sublimits of up to $30.0 million for swing line loans for domestic borrowers in U.S. Dollars (“USD”) and a $20.0 million swing line loan for our German Holding Company and up to $30.0 million for the issuance of standby letters of credit, which Credit Facility may be increased from time-to-time by the greater of $350.0 million and earnings before interest, taxes, depreciation and amortization (“EBITDA”) for the preceding twelve month period in the aggregate through an increase in the Credit Facility, subject to the satisfaction of certain conditions. Borrowings under the Credit Facility bear interest at either the base rate (the per annum interest rate of the highest of the Prime Rate, the Federal Funds Rate plus 50 basis points or the daily London Interbank Offered Rate (“LIBOR”), plus 1.00% ) or at the applicable LIBOR rate, plus a tiered margin based on the ratio of our net consolidated debt to our modified EBITDA, ranging from 0 to 37.5 basis points for base rate loans and 87.5 to 137.5 basis points for LIBOR rate loans. The Credit Agreement contains financial covenants providing that we shall not permit the ratio of our net consolidated debt to our modified EBITDA to be greater than 3.5 to 1; provided that, no more than three times during the term of the Credit Agreement, upon the occurrence of a qualified acquisition for each of our four fiscal quarters immediately following such qualified acquisition, the ratio shall be increased to 4.0 to 1. The Credit Agreement also contains customary limitations on liens securing our indebtedness, fundamental changes (mergers, consolidations, liquidations and dissolutions), asset sales, distributions and acquisitions. As of September 30, 2019 and December 31, 2018 , total unamortized debt issuance costs of $1.1 million and $0.6 million , respectively, were recorded in other noncurrent assets and are being amortized as additional interest expense over the term of the Credit Facility. A portion of these costs relate to our prior revolving credit facility. At September 30, 2019 , we had $27.6 million in outstanding long-term borrowings under the Credit Facility, of which $4.6 million was denominated in Japanese Yen (“Yen”) and $23.0 million was denominated in Euro. These borrowings, together with outstanding letters of credit of $2.5 million , resulted in a borrowing capacity available under the Credit Facility of $269.9 million at September 30, 2019 . Please refer to Note 9, Derivative Financial Instruments , for a discussion of the foreign currency hedges associated with the Credit Facility. Please refer to Note 9, Debt , to the consolidated financial statements in our 2018 Annual Report for additional details regarding our debt agreements.

Derivative Financial Instrument

Derivative Financial Instruments	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Financial Instruments	Derivative Financial Instruments Our ongoing business operations expose us to various risks, such as fluctuating interest rates, foreign currency exchange rates and increasing commodity prices. To manage these market risks, we periodically enter into derivative financial instruments, such as interest rate swaps, options and foreign exchange contracts for periods consistent with, and for notional amounts equal to or less than, the related underlying exposures. We do not purchase or hold any derivative financial instruments for investment or trading purposes. All derivatives are recorded in our condensed consolidated balance sheet at fair value. Foreign Exchange Rate Risk We have entered into forward exchange contracts, designated as fair value hedges, to manage our exposure to fluctuating foreign exchange rates on cross-currency intercompany loans. As of September 30, 2019 , the total amount of these forward exchange contracts was Singapore Dollar (“SGD”) 601.5 million and $13.4 million . As of December 31, 2018 , the total amount of these forward exchange contracts was €10.0 million , SGD 601.5 million and $13.4 million . In addition, we have entered into several foreign currency contracts, designated as cash flow hedges, for periods of up to eighteen months, intended to hedge the currency risk associated with a portion of our forecasted transactions denominated in foreign currencies. As of September 30, 2019 , we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD Euro USD 39.3 — 34.2 Yen 5,921.1 31.8 20.2 SGD 31.9 18.7 4.3 At September 30, 2019 , a portion of our debt consisted of borrowings denominated in currencies other than USD. We have designated our €21.0 million ( $23.0 million ) Euro-denominated borrowings under our Credit Facility as a hedge of our net investment in certain European subsidiaries. A cumulative foreign currency translation gain of $0.6 million pre-tax ( $0.5 million after tax) on this debt was recorded within accumulated other comprehensive loss as of September 30, 2019 . We have also designated our ¥500.0 million ( $4.6 million ) Yen-denominated borrowings under our Credit Facility as a hedge of our net investment in Daikyo. At September 30, 2019 , there was a cumulative foreign currency translation loss of $0.5 million pre-tax ( $0.4 million after tax) on this Yen-denominated debt, which was also included within accumulated other comprehensive loss. Commodity Price Risk Many of our proprietary products are made from synthetic elastomers, which are derived from the petroleum refining process. We purchase the majority of our elastomers via long-term supply contracts, some of which contain clauses that provide for surcharges related to fluctuations in crude oil prices. The following economic hedges did not qualify for hedge accounting treatment since they did not meet the highly effective requirement at inception. From November 2017 through July 2019, we purchased several series of call options for a total of 301,326 barrels of crude oil to mitigate our exposure to such oil-based surcharges and protect operating cash flows with regards to a portion of our forecasted elastomer purchases. As of September 30, 2019 , we had outstanding contracts to purchase 107,909 barrels of crude oil from October 2019 to December 2020, at a weighted-average strike price of $71.15 per barrel. Effects of Derivative Instruments on Financial Position and Results of Operations Please refer to Note 10, Fair Value Measurements , for the balance sheet location and fair values of our derivative instruments as of September 30, 2019 and December 31, 2018 . The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Loss (Gain) Recognized in Income for the Amount of Gain Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2019 2018 2019 2018 Fair Value Hedges: Foreign currency hedge contracts $ 4.3 $ (2.0 ) $ (5.0 ) $ (3.4 ) Other expense (income) Total $ 4.3 $ (2.0 ) $ (5.0 ) $ (3.4 ) We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of (Loss) Gain Recognized in OCI for the Amount of Loss (Gain) Reclassified from Accumulated OCI into Income for the Location of Loss (Gain) Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2019 2018 2019 2018 Fair Value Hedges Foreign currency hedge contracts $ (0.6 ) $ — $ 2.9 $ — Other expense (income) Total $ (0.6 ) $ — $ 2.9 $ — Cash Flow Hedges: Foreign currency hedge contracts $ 0.7 $ 0.1 $ (0.3 ) $ — Net sales Foreign currency hedge contracts 0.6 (0.5 ) (0.2 ) (0.1 ) Cost of goods and services sold Forward treasury locks — — 0.1 0.1 Interest expense Total $ 1.3 $ (0.4 ) $ (0.4 ) $ — Net Investment Hedges: Foreign currency-denominated debt $ 0.7 $ 0.2 $ — $ — Other expense (income) Total $ 0.7 $ 0.2 $ — $ — Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Nine Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Fair Value Hedges Foreign currency hedge contracts $ 3.9 $ — $ (3.3 ) $ — Other expense (income) Total $ 3.9 $ — $ (3.3 ) $ — Cash Flow Hedges: Foreign currency hedge contracts $ 1.0 $ 0.2 $ (0.7 ) $ 0.8 Net sales Foreign currency hedge contracts 1.1 0.9 (0.5 ) 0.4 Cost of goods and services sold Forward treasury locks — — 0.2 0.2 Interest expense Total $ 2.1 $ 1.1 $ (1.0 ) $ 1.4 Net Investment Hedges: Foreign currency-denominated debt $ 0.5 $ 0.7 $ — $ — Other expense (income) Total $ 0.5 $ 0.7 $ — $ — The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of Loss Recognized in Income for the Amount of Loss (Gain) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2019 2018 2019 2018 Commodity call options $ 0.1 $ — $ 0.3 $ (0.5 ) Cost of goods and services sold Total $ 0.1 $ — $ 0.3 $ (0.5 ) For the three and nine months ended September 30, 2019 and 2018 , there was no material ineffectiveness related to our hedges.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1 : Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2 : Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3 : Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) September 30, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 9.9 $ 9.9 $ — $ — Foreign currency contracts 13.2 — 13.2 — Commodity call options 0.1 — 0.1 — $ 23.2 $ 9.9 $ 13.3 $ — Liabilities: Contingent consideration $ 1.8 $ — $ — $ 1.8 Deferred compensation liabilities 11.4 11.4 — — Foreign currency contracts 0.2 — 0.2 — $ 13.4 $ 11.4 $ 0.2 $ 1.8 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 8.7 $ 8.7 $ — $ — Foreign currency contracts 6.5 — 6.5 — $ 15.2 $ 8.7 $ 6.5 $ — Liabilities: Contingent consideration $ 1.7 $ — $ — $ 1.7 Deferred compensation liabilities 9.8 9.8 — — Foreign currency contracts 0.2 — 0.2 — $ 11.7 $ 9.8 $ 0.2 $ 1.7 Deferred compensation assets are included within other noncurrent assets and are valued using a market approach based on quoted market prices in an active market. The fair value of our foreign currency contracts, included within other current and other noncurrent assets, as well as other current and other long-term liabilities, is valued using an income approach based on quoted forward foreign exchange rates and spot rates at the reporting date. The fair value of our commodity call options, included within other current and other noncurrent assets, is valued using a market approach. The fair value of our contingent consideration, included within other current and other long-term liabilities, is discussed further in the section related to Level 3 fair value measurements. The fair value of deferred compensation liabilities is based on quoted prices of the underlying employees’ investment selections and is included within other long-term liabilities. Please refer to Note 9, Derivative Financial Instruments , for further discussion of our derivatives. Level 3 Fair Value Measurements The fair value of the contingent consideration liability related to the SmartDose technology platform (the “SmartDose contingent consideration”) was initially determined using a probability-weighted income approach, and is revalued at each reporting date or more frequently if circumstances dictate. Changes in the fair value of this obligation are recorded as income or expense within other expense (income) in our condensed consolidated statements of income. The significant unobservable inputs used in the fair value measurement of the SmartDose contingent consideration are the sales projections, the probability of success factors, and the discount rate. Significant increases or decreases in any of those inputs in isolation would result in a significantly lower or higher fair value measurement. As development and commercialization of the SmartDose technology platform progresses, we may need to update the sales projections, the probability of success factors, and the discount rate used. This could result in a material increase or decrease to the SmartDose contingent consideration. The following table provides a summary of changes in our Level 3 fair value measurements: ($ in millions) Balance, December 31, 2017 $ 4.9 Decrease in fair value recorded in earnings (2.6 ) Payments (0.6 ) Balance, December 31, 2018 1.7 Increase in fair value recorded in earnings 0.4 Payments (0.3 ) Balance, September 30, 2019 $ 1.8 Other Financial Instruments We believe that the carrying amounts of our cash and cash equivalents and accounts receivable approximate their fair values due to their near-term maturities. The estimated fair value of long-term debt is based on quoted market prices for debt issuances with similar terms and maturities and is classified as Level 2 within the fair value hierarchy. At September 30, 2019 , the estimated fair value of long-term debt was $204.4 million compared to a carrying amount of $195.1 million . At December 31, 2018 , the estimated fair value of long-term debt was $192.6 million and the carrying amount was $196.0 million .

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2019 : ($ in millions) (Losses) gains on derivatives Unrealized gains on investment securities Defined benefit pension and other postretirement plans Foreign currency translation Total Balance, December 31, 2018 $ (0.4 ) $ 0.4 $ (40.4 ) $ (113.8 ) $ (154.2 ) Other comprehensive income (loss) before reclassifications 6.0 — 0.6 (20.1 ) (13.5 ) Amounts reclassified out (4.3 ) — 1.6 — (2.7 ) Other comprehensive income (loss), net of tax 1.7 — 2.2 (20.1 ) (16.2 ) Balance, September 30, 2019 $ 1.3 $ 0.4 $ (38.2 ) $ (133.9 ) $ (170.4 ) A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Nine Months Ended Location on Statement of Income Detail of components 2019 2018 2019 2018 Gains (losses) on derivatives: Foreign currency contracts $ 0.3 $ 0.1 $ 0.8 $ (0.8 ) Net sales Foreign currency contracts 0.3 — 0.8 (0.7 ) Cost of goods and services sold Foreign currency contracts (4.3 ) — 5.0 — Other expense (income) Forward treasury locks (0.1 ) (0.1 ) (0.3 ) (0.3 ) Interest expense Total before tax (3.8 ) — 6.3 (1.8 ) Tax expense 1.3 — (2.0 ) 0.4 Net of tax $ (2.5 ) $ — $ 4.3 $ (1.4 ) Amortization of defined benefit pension and other postretirement plans: Prior service credit $ 0.1 $ 0.5 $ 0.4 $ 1.6 (a) Actuarial gains (losses) 0.2 (0.2 ) 0.2 (1.0 ) (a) Settlements (2.7 ) — (2.7 ) — (a) Total before tax (2.4 ) 0.3 (2.1 ) 0.6 Tax expense 0.6 — 0.5 (0.1 ) Net of tax $ (1.8 ) $ 0.3 $ (1.6 ) $ 0.5 Total reclassifications for the period, net of tax $ (4.3 ) $ 0.3 $ 2.7 $ (0.9 ) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details.

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	Shareholders ’ Equity The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019 : Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total ($ in millions) Balance, December 31, 2018 75.3 $ 18.8 $ 282.0 1.2 $ (103.7 ) $ 1,353.4 $ (154.2 ) $ 1,396.3 Net income — — — — — 55.4 — 55.4 Activity related to stock-based compensation — — (3.5 ) (0.2 ) 14.2 — — 10.7 Shares purchased under share repurchase program — — — 0.8 (83.1 ) — — (83.1 ) Dividends declared ($0.15 per share) — — — — — (10.6 ) — (10.6 ) Other comprehensive income, net of tax — — — — — — 0.8 0.8 Balance, March 31, 2019 75.3 $ 18.8 $ 278.5 1.8 $ (172.6 ) $ 1,398.2 $ (153.4 ) $ 1,369.5 Net income — — — — — 66.1 — 66.1 Activity related to stock-based compensation — — (5.1 ) (0.2 ) 24.8 — — 19.7 Dividends declared ($0.15 per share) — — — — — (11.4 ) — (11.4 ) Other comprehensive income, net of tax — — — — — — 1.2 1.2 Balance, June 30, 2019 75.3 $ 18.8 $ 273.4 1.6 $ (147.8 ) $ 1,452.9 $ (152.2 ) $ 1,445.1 Net income — — — — — 56.3 — 56.3 Activity related to stock-based compensation — — (4.9 ) (0.3 ) 21.2 — — 16.3 Dividends declared ($0.16 per share) — — — — — (11.9 ) — (11.9 ) Other comprehensive loss, net of tax — — — — — — (18.2 ) (18.2 ) Balance, September 30, 2019 75.3 $ 18.8 $ 268.5 1.3 $ (126.6 ) $ 1,497.3 $ (170.4 ) $ 1,487.6 The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2018 : Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total ($ in millions) Balance, December 31, 2017 75.2 $ 18.8 $ 309.3 1.3 $ (109.1 ) $ 1,178.2 $ (117.3 ) $ 1,279.9 Effect of modified retrospective application of a new accounting standard — — — — — 11.4 — 11.4 Net income — — — — — 43.6 — 43.6 Activity related to stock-based compensation 0.1 — (0.8 ) (0.1 ) 8.0 — — 7.2 Shares purchased under share repurchase program — — — 0.5 (47.9 ) — — (47.9 ) Dividends declared ($0.14 per share) — — — — — (10.4 ) — (10.4 ) Other comprehensive income, net of tax — — — — — — 21.5 21.5 Balance, March 31, 2018 75.3 $ 18.8 $ 308.5 1.7 $ (149.0 ) $ 1,222.8 $ (95.8 ) $ 1,305.3 Net income — — — — — 56.1 — 56.1 Activity related to stock-based compensation — — (3.8 ) (0.2 ) 16.0 — — 12.2 Shares purchased under share repurchase program — — — 0.3 (22.9 ) — — (22.9 ) Dividends declared ($0.14 per share) — — — — — (20.9 ) — (20.9 ) Other comprehensive loss, net of tax — — — — — — (47.9 ) (47.9 ) Balance, June 30, 2018 75.3 $ 18.8 $ 304.7 1.8 $ (155.9 ) $ 1,258.0 $ (143.7 ) $ 1,281.9 Net income — — — — — 55.2 — 55.2 Activity related to stock-based compensation — — (21.9 ) (0.6 ) 47.2 — — 25.3 Dividends declared ($0.15 per share) — — — — — (0.5 ) — (0.5 ) Other comprehensive loss, net of tax — — — — — — (10.1 ) (10.1 ) Balance, September 30, 2018 75.3 $ 18.8 $ 282.8 1.2 $ (108.7 ) $ 1,312.7 $ (153.8 ) $ 1,351.8

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Compensation	Stock-Based Compensation The West Pharmaceutical Services, Inc. 2016 Omnibus Incentive Compensation Plan (the “2016 Plan”) provides for the granting of stock options, stock appreciation rights, restricted stock awards and performance awards to employees and non-employee directors. A committee of the Board of Directors determines the terms and conditions of awards to be granted. Vesting requirements vary by award. At September 30, 2019 , there were 3,110,708 shares remaining in the 2016 Plan for future grants. During the nine months ended September 30, 2019 , we granted 345,400 stock options at a weighted average exercise price of $102.59 per share based on the grant-date fair value of our stock to employees under the 2016 Plan. The weighted average grant date fair value of options granted was $24.53 per share as determined by the Black-Scholes option valuation model using the following weighted average assumptions: a risk-free interest rate of 2.3% ; expected life of 5.6 years based on prior experience; stock volatility of 22.5% based on historical data; and a dividend yield of 0.7% . Stock option expense is recognized over the vesting period, net of forfeitures. During the nine months ended September 30, 2019 , we granted 82,646 stock-settled performance share unit (“PSU”) awards at a weighted average grant-date fair value of $102.59 per share to eligible employees. These awards are earned based on the Company’s performance against pre-established targets, including annual growth rate of revenue and return on invested capital, over a specified performance period. Depending on the achievement of the targets, recipients of stock-settled PSU awards are entitled to receive a certain number of shares of common stock. Shares earned under PSU awards may vary from 0% to 200% of an employee’s targeted award. The fair value of stock-settled PSU awards is based on the market price of our stock at the grant date and is recognized as expense over the performance period, adjusted for estimated target outcomes and net of forfeitures. During the nine months ended September 30, 2019 , we granted 11,631 stock-settled restricted share unit (“RSU”) awards at a weighted average grant-date fair value of $112.49 per share to eligible employees. These awards are earned over a specified performance period. The fair value of stock-settled RSU awards is based on the market price of our stock at the grant date and is recognized as expense over the vesting period, net of forfeitures. Total stock-based compensation expense was $5.4 million and $18.8 million for the three and nine months ended September 30, 2019 , respectively. For the three and nine months ended September 30, 2018 , stock-based compensation expense was $5.3 million and $14.7 million , respectively.

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Benefit Plans	Benefit Plans The components of net periodic benefit cost for the three months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 0.4 $ 2.6 $ — $ — $ 0.4 $ 2.6 Interest cost 1.9 2.3 0.1 0.1 2.0 2.4 Expected return on assets (3.1 ) (3.9 ) — — (3.1 ) (3.9 ) Amortization of prior service credit 0.1 (0.3 ) (0.2 ) (0.2 ) (0.1 ) (0.5 ) Recognized actuarial losses (gains) 0.5 0.9 (0.7 ) (0.7 ) (0.2 ) 0.2 Settlements 2.7 — — — 2.7 — Net periodic benefit cost $ 2.5 $ 1.6 $ (0.8 ) $ (0.8 ) $ 1.7 $ 0.8 Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 U.S. plans $ 2.0 $ 1.0 $ (0.8 ) $ (0.8 ) $ 1.2 $ 0.2 International plans 0.5 0.6 — — 0.5 0.6 Net periodic benefit cost $ 2.5 $ 1.6 $ (0.8 ) $ (0.8 ) $ 1.7 $ 0.8 The components of net periodic benefit cost for the nine months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 1.1 $ 8.1 $ — $ — $ 1.1 $ 8.1 Interest cost 6.8 7.0 0.2 0.2 7.0 7.2 Expected return on assets (8.9 ) (11.7 ) — — (8.9 ) (11.7 ) Amortization of prior service credit 0.1 (1.1 ) (0.5 ) (0.5 ) (0.4 ) (1.6 ) Recognized actuarial losses (gains) 1.6 2.8 (1.8 ) (1.8 ) (0.2 ) 1.0 Settlements 2.7 — — — 2.7 — Net periodic benefit cost $ 3.4 $ 5.1 $ (2.1 ) $ (2.1 ) $ 1.3 $ 3.0 Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 U.S. plans $ 1.9 $ 3.5 $ (2.1 ) $ (2.1 ) $ (0.2 ) $ 1.4 International plans 1.5 1.6 — — 1.5 1.6 Net periodic benefit cost $ 3.4 $ 5.1 $ (2.1 ) $ (2.1 ) $ 1.3 $ 3.0 During the three and nine months ended September 30, 2019 , we recorded a $2.7 million pension settlement charge within other nonoperating expense (income), as we determined that normal-course lump-sum payments for each of our U.S. qualified and non-qualified defined benefit pension plans exceeded the threshold for settlement accounting under U.S. GAAP for the year. Effective January 1, 2019, except for interest crediting, benefit accruals under these defined benefit pension plans ceased. During the three and nine months ended September 30, 2019 , we contributed $2.6 million to our U.S. qualified defined benefit pension plan.

Other Expense

Other Expense	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
Other Expense	Other Expense (Income) Other expense (income) consists of: Three Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Restructuring and related charges: Severance and post-employment benefits $ 0.6 $ 0.1 $ 2.2 $ 3.4 Asset-related charges 0.1 0.4 0.1 0.8 Other charges 1.1 0.7 1.5 2.5 Total restructuring and related charges 1.8 1.2 3.8 6.7 Argentina currency devaluation 1.0 1.1 1.0 1.1 Development and licensing income (0.2 ) (0.2 ) (0.6 ) (0.6 ) Contingent consideration 0.1 0.2 0.4 0.8 Other items 3.7 (2.5 ) (3.0 ) (4.0 ) Total other expense (income) $ 6.4 $ (0.2 ) $ 1.6 $ 4.0 Restructuring and Related Charges In February 2018, our Board of Directors approved a restructuring plan designed to realign our manufacturing capacity with demand. These changes are expected to be implemented over a period of up to twenty-four months from the date of approval. The plan will require restructuring and related charges of approximately $16.0 million . Since its approval, we have recorded $12.6 million in restructuring and related charges associated with this plan. During the three months ended September 30, 2019 , we recorded $1.8 million in restructuring and related charges associated with this plan, consisting of $0.6 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.1 million for other non-cash charges. During the three months ended September 30, 2018 , we recorded $1.2 million in restructuring and related charges associated with this plan, consisting of $0.1 million for severance charges, $0.4 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $0.7 million for other non-cash charges. During the nine months ended September 30, 2019 , we recorded $3.8 million in restructuring and related charges associated with this plan, consisting of $2.2 million for severance charges, $0.1 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $1.5 million for other non-cash charges. During the nine months ended September 30, 2018 , we recorded $6.7 million in restructuring and related charges associated with this plan, consisting of $3.4 million for severance charges, $0.8 million for non-cash asset write-downs associated with the discontinued use of certain equipment, and $2.5 million for other non-cash charges. The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan: ($ in millions) Severance and benefits Asset-related charges Other charges Total Balance, December 31, 2018 $ 2.3 $ — $ — $ 2.3 Charges 2.2 0.1 1.5 3.8 Cash payments (2.0 ) — — (2.0 ) Non-cash asset write-downs — (0.1 ) (1.5 ) (1.6 ) Balance, September 30, 2019 $ 2.5 $ — $ — $ 2.5 On February 15, 2016, our Board of Directors approved a restructuring plan designed to repurpose several of our production facilities in support of growing high-value proprietary products and to realign operational and commercial activities to meet the needs of our new market-focused commercial organization. Our remaining restructuring obligations related to the 2016 restructuring plan as of September 30, 2019 were $0.2 million . Other Items During the three and nine months ended September 30, 2019 , we recorded a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. During the three and nine months ended September 30, 2018 , we recorded a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018. During both the three and nine months ended September 30, 2019 and 2018 , we recorded development income of $0.2 million and $0.6 million , respectively, related to a nonrefundable customer payment of $20.0 million received in June 2013 in return for the exclusive use of the SmartDose technology platform within a specific therapeutic area. Please refer to Note 3, Revenue , for additional information. Contingent consideration represents changes in the fair value of the SmartDose contingent consideration. Please refer to Note 10, Fair Value Measurements , for additional details. Other items consist of foreign exchange transaction gains and losses, gains and losses on the sale of fixed assets, and miscellaneous income and charges. Other items changed by $6.2 million for the three months ended September 30, 2019 , as compared to the same period in 2018 , primarily as a result of foreign exchange transaction losses of $5.1 million during the three months ended September 30, 2019 , as compared to foreign exchange transaction gains of $2.7 million during the three months ended September 30, 2018 . Other items decreased by $1.0 million for the nine months ended September 30, 2019 , as compared to the same period in 2018 , primarily due to losses on the sale of fixed assets during the nine months ended September 30, 2019 .

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The tax provision for interim periods is determined using the estimated annual effective consolidated tax rate, based on the current estimate of full-year earnings before taxes, adjusted for the impact of discrete quarterly items. The provision for income taxes was $10.9 million and $8.0 million for the three months ended September 30, 2019 and 2018 , respectively, and the effective tax rate was 16.8% and 13.1% , respectively. The provision for income taxes was $42.5 million and $26.5 million for the nine months ended September 30, 2019 and 2018 , respectively, and the effective tax rate was 19.8% and 15.1% , respectively. During the three and nine months ended September 30, 2019 , we recorded a tax benefit of $1.0 million due to the impact of federal law changes enacted during the quarter. During the three and nine months ended September 30, 2018 , we recorded a net tax charge of $0.4 million and a net tax benefit of $4.1 million , respectively, for the estimated impact of the 2017 Tax Act. Please refer to Note 16, Income Taxes , to the consolidated financial statements in our 2018 Annual Report for further discussion.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies From time to time, we are involved in product liability matters and other legal proceedings and claims generally incidental to our normal business activities. We accrue for loss contingencies when it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. While the outcome of current proceedings cannot be accurately predicted, we believe their ultimate resolution should not have a material adverse effect on our business, financial condition, results of operations or liquidity. There have been no significant changes to the commitments and contingencies included in our 2018 Annual Report . On January 1, 2019, we adopted ASC 842. Please refer to Note 6, Leases , for additional information.

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information Our business operations are organized into two reportable segments, Proprietary Products and Contract-Manufactured Products. Our Proprietary Products reportable segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. Our Contract-Manufactured Products reportable segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. We evaluate the performance of our segments based upon, among other things, segment net sales and operating profit. Segment operating profit excludes general corporate costs, which include executive and director compensation, stock-based compensation, adjustments to annual incentive plan expense for over- or under-attainment of targets, certain pension and other retirement benefit costs, and other corporate facilities and administrative expenses not allocated to the segments. Also excluded are items that we consider not representative of ongoing operations. Such items are referred to as other unallocated items and generally include restructuring and related charges, certain asset impairments and other specifically-identified income or expense items. The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Net sales: Proprietary Products $ 345.2 $ 325.2 $ 1,045.9 $ 997.4 Contract-Manufactured Products 111.1 106.7 323.6 297.7 Intersegment sales elimination (0.2 ) (0.2 ) (0.2 ) (0.2 ) Consolidated net sales $ 456.1 $ 431.7 $ 1,369.3 $ 1,294.9 Operating profit (loss): Proprietary Products $ 72.9 $ 68.2 $ 238.7 $ 202.7 Contract-Manufactured Products 11.6 11.2 33.5 29.7 Corporate (14.4 ) (16.3 ) (48.9 ) (50.1 ) Other unallocated items (2.8 ) (2.3 ) (4.8 ) (7.8 ) Total operating profit $ 67.3 $ 60.8 $ 218.5 $ 174.5 Interest expense 2.1 2.0 6.4 6.1 Interest income (1.0 ) (0.5 ) (2.5 ) (1.4 ) Other nonoperating expense (income) 1.3 (1.8 ) 0.2 (5.1 ) Income before income taxes $ 64.9 $ 61.1 $ 214.4 $ 174.9 The intersegment sales elimination, which is required for the presentation of consolidated net sales, represents the elimination of components sold between our segments. Other unallocated items during the three and nine months ended September 30, 2019 consisted of $1.8 million and $3.8 million , respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2019 , other unallocated items included a charge of $1.0 million as a result of the continued devaluation of Argentina’s currency. Other unallocated items during the three and nine months ended September 30, 2018 consisted of $1.2 million and $6.7 million , respectively, in restructuring and related charges. In addition, during the three and nine months ended September 30, 2018, other unallocated items included a charge of $1.1 million related to the classification of Argentina’s economy as highly inflationary under U.S. GAAP as of July 1, 2018. Please refer to Note 15, Other Expense (Income) , for further discussion of these items.

Subsequent Event (Notes)

Subsequent Event (Notes)	9 Months Ended
	Sep. 30, 2019
Subsequent Events [Abstract]
Subsequent Events [Text Block]	Subsequent Event On October 15, 2019, we entered into an Amendment Agreement (the “Amendment”) with Daikyo, amending certain commercial agreements between the parties in order to make each party’s rights under such agreements exclusive. The Amendment amends the Amended and Restated Technology Exchange and CrossLicense Agreement and Distributorship Agreements, each dated and effective January 18, 2017, as modified by the Letter Agreement dated and effective July 2, 2018. In addition, on October 16, 2019, we announced that we increased our ownership interest in Daikyo to 49% . We believe that the increase in ownership interest will not have a material impact on our financial statements.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation : The condensed consolidated financial statements included in this report are unaudited and have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial reporting and U.S. Securities and Exchange Commission (“SEC”) regulations. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with U.S. GAAP have been condensed or omitted. In the opinion of management, these financial statements include all adjustments, which are of a normal recurring nature, necessary for a fair statement of the financial position, results of operations, cash flows and the change in equity for the periods presented. The condensed consolidated financial statements for the three and nine months ended September 30, 2019 should be read in conjunction with the consolidated financial statements and notes thereto of West Pharmaceutical Services, Inc. and its majority-owned subsidiaries (which may be referred to as “West”, the “Company”, “we”, “us” or “our”) appearing in our Annual Report on Form 10-K for the year ended December 31, 2018 (the “ 2018 Annual Report ”). The results of operations for any interim period are not necessarily indicative of results for the full year. In April 2019, we acquired the business of our distributor in South Korea for $18.9 million . As a result of the acquisition, we recorded inventories, property, plant and equipment, goodwill and a customer relationships intangible asset of $4.5 million , $0.6 million , $2.6 million and $11.2 million , respectively. The goodwill was recorded within our Proprietary Products reportable segment. The results of this acquisition have been included in our condensed consolidated financial statements since the acquisition date. As of April 1, 2017, our consolidated financial statements exclude the results of our Venezuelan subsidiary. Please refer to Note 15, Other Expense , to the consolidated financial statements in our 2018 Annual Report for further discussion.
New Accounting Standards	Recently Adopted Standards In August 2018, the SEC adopted a final release which would eliminate or modify certain disclosure requirements that are redundant, outdated, or duplicative of U.S. GAAP or other regulatory requirements. Among other changes, the amendments provide that disclosure requirements related to the analysis of shareholders’ equity are expanded for interim purposes. An analysis of the changes in each caption of shareholders’ equity presented in the balance sheet must be provided in a note or separate statement, as well as the amount of dividends per share for each class of shares. We provided this disclosure beginning in the first quarter of 2019. Please refer to Note 12, Shareholders ’ Equity . In June 2018, the Financial Accounting Standards Board (“FASB”) issued guidance which expands the scope of accounting for share-based payment arrangements to include share-based payment transactions for acquiring goods and services from nonemployees. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2018, the FASB issued guidance to address a specific consequence of the Tax Cuts and Jobs Acts (the “2017 Tax Act”) by allowing a reclassification from accumulated other comprehensive income (loss) to retained earnings for stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis, but elected to not reclassify from accumulated other comprehensive income (loss) to retained earnings the stranded tax effects resulting from the 2017 Tax Act’s reduction of the U.S. federal corporate income tax rate. In August 2017, the FASB issued guidance which expands and refines hedge accounting for both nonfinancial and financial risk components and aligns the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, on a prospective basis. The adoption did not have a material impact on our financial statements. In February 2016, the FASB issued guidance on the accounting for leases, Accounting Standards Codification (“ASC”) Topic 842 (“ASC 842”). This guidance requires lessees to recognize lease assets and lease liabilities on the balance sheet and to expand disclosures about leasing arrangements, both qualitative and quantitative. In terms of transition, the guidance requires adoption based upon a modified retrospective approach. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018. Early adoption was permitted. We adopted this guidance as of January 1, 2019, using the modified retrospective approach that allows companies to apply ASC 842 as of the effective date and on a prospective basis. Please refer to Note 6, Leases , for additional information. Standards Issued Not Yet Adopted In April 2019, the FASB issued guidance which clarifies and improves areas of guidance related to the new credit losses, hedging, and recognition and measurement standards. This guidance is effective for the same fiscal years in which the original standards are effective or, if already implemented, annual periods beginning after the issuance of this guidance. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance to align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). The accounting for the service element of a hosting arrangement that is a service contract is not affected by this update. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted, including adoption in any interim period. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance which modifies the disclosure requirements for defined benefit pension plans and other postretirement plans. The guidance removes disclosures that no longer are considered cost beneficial, clarifies the specific requirements of disclosures, and adds disclosure requirements identified as relevant. This guidance is effective for fiscal years ending after December 15, 2020. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In August 2018, the FASB issued guidance which modifies the disclosure requirements on fair value measurements by removing, modifying, or adding certain disclosures. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements. In June 2016, the FASB issued guidance which provides financial statement users with more decision-useful information about the expected credit losses on financial instruments and other commitments held by a reporting entity at each reporting date. This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2019. Early adoption is permitted. We believe that the adoption of this guidance will not have a material impact on our financial statements.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2019
Revenue [Abstract]
Disaggregation of Revenue [Table Text Block]	The following table presents the approximate percentage of our net sales by market group: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Biologics 26 % 21 % 25 % 21 % Generics 20 % 21 % 20 % 21 % Pharma 30 % 34 % 31 % 35 % Contract-Manufactured Products 24 % 24 % 24 % 23 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by product category: Three Months Ended Nine Months Ended 2019 2018 2019 2018 High-Value Components 42 % 41 % 43 % 42 % Standard Packaging 28 % 31 % 29 % 32 % Delivery Devices 6 % 4 % 4 % 3 % Contract-Manufactured Products 24 % 24 % 24 % 23 % 100 % 100 % 100 % 100 % The following table presents the approximate percentage of our net sales by geographic location: Three Months Ended Nine Months Ended 2019 2018 2019 2018 Americas 48 % 51 % 48 % 48 % Europe, Middle East, Africa 44 % 41 % 44 % 44 % Asia Pacific 8 % 8 % 8 % 8 % 100 % 100 % 100 % 100 %
Change in Contract with Customer, Asset and Liability [Abstract]	The following table summarizes our contract assets and liabilities, excluding contract assets included in accounts receivable, net: ($ in millions) Contract assets, December 31, 2018 $ 9.1 Contract assets, September 30, 2019 9.4 Change in contract assets - increase (decrease) $ 0.3 Deferred income, December 31, 2018 $ (33.4 ) Deferred income, September 30, 2019 (30.9 ) Change in deferred income - decrease (increase) $ 2.5

Net Income Per Share (Tables)

Net Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2019
Earnings Per Share [Abstract]
Reconciliation of Basic to Diluted Net Income Per Share	The following table reconciles the shares used in the calculation of basic net income per share to those used for diluted net income per share: Three Months Ended Nine Months Ended (in millions) 2019 2018 2019 2018 Net income $ 56.3 $ 55.2 $ 177.8 $ 154.9 Weighted average common shares outstanding 74.0 73.9 73.9 73.9 Dilutive effect of equity awards, based on the treasury stock method 1.5 1.8 1.4 1.5 Weighted average shares assuming dilution 75.5 75.7 75.3 75.4

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories are valued at the lower of cost (on a first-in, first-out basis) and net realizable value. Inventory balances were as follows: ($ in millions) September 30, December 31, Raw materials $ 99.2 $ 90.4 Work in process 38.3 42.2 Finished goods 92.9 81.9 $ 230.4 $ 214.5

Leases Leases (Tables)

Leases Leases (Tables)	9 Months Ended
	Sep. 30, 2019
Leases [Abstract]
Lease, Cost [Table Text Block]	The components of lease expense were as follows: ($ in millions) Three Months Ended Nine Months Ended Operating lease cost $ 3.4 $ 9.7 Short-term lease cost 0.1 0.5 Variable lease cost 0.8 2.3 Total lease cost $ 4.3 $ 12.5
Lessee, Lease Cash Flow and Supplemental Information [Table Text Block]	Supplemental information related to leases was as follows: ($ in millions) Three Months Ended Nine Months Ended Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 3.2 $ 9.4 Right-of-use assets obtained in exchange for new operating lease liabilities $ 0.3 $ 8.4
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	Maturities of lease liabilities as of September 30, 2019 were as follows: ($ in millions) Operating Year Leases 2019 (remaining three months) $ 3.4 2020 12.0 2021 10.2 2022 8.3 2023 7.7 Thereafter 48.1 89.7 Less: imputed lease interest (16.4 ) Total lease liabilities $ 73.3
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	of December 31, 2018 were as follows: ($ in millions) Operating Year Leases 2019 $ 13.0 2020 10.5 2021 7.8 2022 6.9 2023 5.5 Thereafter 37.8 Total $ 81.5

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2019
Debt Disclosure [Abstract]
Long-term Debt Obligations, Net of Current Maturities	The following table summarizes our long-term debt obligations, net of unamortized debt issuance costs and current maturities. The interest rates shown in parentheses are as of September 30, 2019 . ($ in millions) September 30, December 31, Note payable, due December 31, 2019 $ — $ 0.1 Credit Facility, due October 15, 2020 — 28.6 Credit Facility, due March 28, 2024 (0.875%) 27.6 — Series A notes, due July 5, 2022 (3.67%) 42.0 42.0 Series B notes, due July 5, 2024 (3.82%) 53.0 53.0 Series C notes, due July 5, 2027 (4.02%) 73.0 73.0 195.6 196.7 Less: unamortized debt issuance costs 0.5 0.6 Total debt 195.1 196.1 Less: current portion of long-term debt — 0.1 Long-term debt, net $ 195.1 $ 196.0

Derivative Financial Instrume_2

Derivative Financial Instruments (Tables)	9 Months Ended
	Sep. 30, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Foreign Currency Contracts	As of September 30, 2019 , we had outstanding foreign currency contracts to purchase and sell certain pairs of currencies, as follows: (in millions) Sell Currency Purchase USD Euro USD 39.3 — 34.2 Yen 5,921.1 31.8 20.2 SGD 31.9 18.7 4.3
Effects of Derivative Instruments on Other Comprehensive Income ('OCI') and Earnings	The following table summarizes the effects of derivative instruments designated as fair value hedges on the condensed consolidated statements of income: Amount of Loss (Gain) Recognized in Income for the Amount of Gain Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2019 2018 2019 2018 Fair Value Hedges: Foreign currency hedge contracts $ 4.3 $ (2.0 ) $ (5.0 ) $ (3.4 ) Other expense (income) Total $ 4.3 $ (2.0 ) $ (5.0 ) $ (3.4 ) We recognize in earnings the initial value of forward point components on a straight-line basis over the life of the fair value hedge. The following tables summarize the effects of derivative instruments designated as fair value, cash flow, and net investment hedges on other comprehensive income (“OCI”) and earnings, net of tax: Amount of (Loss) Gain Recognized in OCI for the Amount of Loss (Gain) Reclassified from Accumulated OCI into Income for the Location of Loss (Gain) Reclassified from Accumulated OCI into Income Three Months Ended Three Months Ended ($ in millions) 2019 2018 2019 2018 Fair Value Hedges Foreign currency hedge contracts $ (0.6 ) $ — $ 2.9 $ — Other expense (income) Total $ (0.6 ) $ — $ 2.9 $ — Cash Flow Hedges: Foreign currency hedge contracts $ 0.7 $ 0.1 $ (0.3 ) $ — Net sales Foreign currency hedge contracts 0.6 (0.5 ) (0.2 ) (0.1 ) Cost of goods and services sold Forward treasury locks — — 0.1 0.1 Interest expense Total $ 1.3 $ (0.4 ) $ (0.4 ) $ — Net Investment Hedges: Foreign currency-denominated debt $ 0.7 $ 0.2 $ — $ — Other expense (income) Total $ 0.7 $ 0.2 $ — $ — Amount of Gain (Loss) Recognized in OCI for the Amount of (Gain) Loss Reclassified from Accumulated OCI into Income for the Location of (Gain) Loss Reclassified from Accumulated OCI into Income Nine Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Fair Value Hedges Foreign currency hedge contracts $ 3.9 $ — $ (3.3 ) $ — Other expense (income) Total $ 3.9 $ — $ (3.3 ) $ — Cash Flow Hedges: Foreign currency hedge contracts $ 1.0 $ 0.2 $ (0.7 ) $ 0.8 Net sales Foreign currency hedge contracts 1.1 0.9 (0.5 ) 0.4 Cost of goods and services sold Forward treasury locks — — 0.2 0.2 Interest expense Total $ 2.1 $ 1.1 $ (1.0 ) $ 1.4 Net Investment Hedges: Foreign currency-denominated debt $ 0.5 $ 0.7 $ — $ — Other expense (income) Total $ 0.5 $ 0.7 $ — $ — The following table summarizes the effects of derivative instruments not designated as hedges on the condensed consolidated statements of income: Amount of Loss Recognized in Income for the Amount of Loss (Gain) Recognized in Income for the Three Months Ended Nine Months Ended Location on Statement of Income ($ in millions) 2019 2018 2019 2018 Commodity call options $ 0.1 $ — $ 0.3 $ (0.5 ) Cost of goods and services sold Total $ 0.1 $ — $ 0.3 $ (0.5 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of Assets and Liabilities Measured at Fair Value	The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Basis of Fair Value Measurements ($ in millions) September 30, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 9.9 $ 9.9 $ — $ — Foreign currency contracts 13.2 — 13.2 — Commodity call options 0.1 — 0.1 — $ 23.2 $ 9.9 $ 13.3 $ — Liabilities: Contingent consideration $ 1.8 $ — $ — $ 1.8 Deferred compensation liabilities 11.4 11.4 — — Foreign currency contracts 0.2 — 0.2 — $ 13.4 $ 11.4 $ 0.2 $ 1.8 Balance at Basis of Fair Value Measurements ($ in millions) December 31, Level 1 Level 2 Level 3 Assets: Deferred compensation assets $ 8.7 $ 8.7 $ — $ — Foreign currency contracts 6.5 — 6.5 — $ 15.2 $ 8.7 $ 6.5 $ — Liabilities: Contingent consideration $ 1.7 $ — $ — $ 1.7 Deferred compensation liabilities 9.8 9.8 — — Foreign currency contracts 0.2 — 0.2 — $ 11.7 $ 9.8 $ 0.2 $ 1.7
Summary of Changes in Level 3 Fair Value Measurements	The following table provides a summary of changes in our Level 3 fair value measurements: ($ in millions) Balance, December 31, 2017 $ 4.9 Decrease in fair value recorded in earnings (2.6 ) Payments (0.6 ) Balance, December 31, 2018 1.7 Increase in fair value recorded in earnings 0.4 Payments (0.3 ) Balance, September 30, 2019 $ 1.8

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2019
Equity [Abstract]
Components of Accumulated Other Comprehensive Loss	The following table presents the changes in the components of accumulated other comprehensive loss, net of tax, for the nine months ended September 30, 2019 : ($ in millions) (Losses) gains on derivatives Unrealized gains on investment securities Defined benefit pension and other postretirement plans Foreign currency translation Total Balance, December 31, 2018 $ (0.4 ) $ 0.4 $ (40.4 ) $ (113.8 ) $ (154.2 ) Other comprehensive income (loss) before reclassifications 6.0 — 0.6 (20.1 ) (13.5 ) Amounts reclassified out (4.3 ) — 1.6 — (2.7 ) Other comprehensive income (loss), net of tax 1.7 — 2.2 (20.1 ) (16.2 ) Balance, September 30, 2019 $ 1.3 $ 0.4 $ (38.2 ) $ (133.9 ) $ (170.4 )
Reclassification out of Accumulated Other Comprehensive Loss	A summary of the reclassifications out of accumulated other comprehensive loss is presented in the following table: ($ in millions) Three Months Ended Nine Months Ended Location on Statement of Income Detail of components 2019 2018 2019 2018 Gains (losses) on derivatives: Foreign currency contracts $ 0.3 $ 0.1 $ 0.8 $ (0.8 ) Net sales Foreign currency contracts 0.3 — 0.8 (0.7 ) Cost of goods and services sold Foreign currency contracts (4.3 ) — 5.0 — Other expense (income) Forward treasury locks (0.1 ) (0.1 ) (0.3 ) (0.3 ) Interest expense Total before tax (3.8 ) — 6.3 (1.8 ) Tax expense 1.3 — (2.0 ) 0.4 Net of tax $ (2.5 ) $ — $ 4.3 $ (1.4 ) Amortization of defined benefit pension and other postretirement plans: Prior service credit $ 0.1 $ 0.5 $ 0.4 $ 1.6 (a) Actuarial gains (losses) 0.2 (0.2 ) 0.2 (1.0 ) (a) Settlements (2.7 ) — (2.7 ) — (a) Total before tax (2.4 ) 0.3 (2.1 ) 0.6 Tax expense 0.6 — 0.5 (0.1 ) Net of tax $ (1.8 ) $ 0.3 $ (1.6 ) $ 0.5 Total reclassifications for the period, net of tax $ (4.3 ) $ 0.3 $ 2.7 $ (0.9 ) (a) These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details.

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018
Equity [Abstract]
Schedule of Stockholders Equity [Table Text Block]	The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2019 : Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total ($ in millions) Balance, December 31, 2018 75.3 $ 18.8 $ 282.0 1.2 $ (103.7 ) $ 1,353.4 $ (154.2 ) $ 1,396.3 Net income — — — — — 55.4 — 55.4 Activity related to stock-based compensation — — (3.5 ) (0.2 ) 14.2 — — 10.7 Shares purchased under share repurchase program — — — 0.8 (83.1 ) — — (83.1 ) Dividends declared ($0.15 per share) — — — — — (10.6 ) — (10.6 ) Other comprehensive income, net of tax — — — — — — 0.8 0.8 Balance, March 31, 2019 75.3 $ 18.8 $ 278.5 1.8 $ (172.6 ) $ 1,398.2 $ (153.4 ) $ 1,369.5 Net income — — — — — 66.1 — 66.1 Activity related to stock-based compensation — — (5.1 ) (0.2 ) 24.8 — — 19.7 Dividends declared ($0.15 per share) — — — — — (11.4 ) — (11.4 ) Other comprehensive income, net of tax — — — — — — 1.2 1.2 Balance, June 30, 2019 75.3 $ 18.8 $ 273.4 1.6 $ (147.8 ) $ 1,452.9 $ (152.2 ) $ 1,445.1 Net income — — — — — 56.3 — 56.3 Activity related to stock-based compensation — — (4.9 ) (0.3 ) 21.2 — — 16.3 Dividends declared ($0.16 per share) — — — — — (11.9 ) — (11.9 ) Other comprehensive loss, net of tax — — — — — — (18.2 ) (18.2 ) Balance, September 30, 2019 75.3 $ 18.8 $ 268.5 1.3 $ (126.6 ) $ 1,497.3 $ (170.4 ) $ 1,487.6	The following table presents the changes in shareholders’ equity for the nine months ended September 30, 2018 : Common Shares Issued Common Stock Capital in Excess of Par Value Number of Treasury Shares Treasury Stock Retained earnings Accumulated other comprehensive loss Total ($ in millions) Balance, December 31, 2017 75.2 $ 18.8 $ 309.3 1.3 $ (109.1 ) $ 1,178.2 $ (117.3 ) $ 1,279.9 Effect of modified retrospective application of a new accounting standard — — — — — 11.4 — 11.4 Net income — — — — — 43.6 — 43.6 Activity related to stock-based compensation 0.1 — (0.8 ) (0.1 ) 8.0 — — 7.2 Shares purchased under share repurchase program — — — 0.5 (47.9 ) — — (47.9 ) Dividends declared ($0.14 per share) — — — — — (10.4 ) — (10.4 ) Other comprehensive income, net of tax — — — — — — 21.5 21.5 Balance, March 31, 2018 75.3 $ 18.8 $ 308.5 1.7 $ (149.0 ) $ 1,222.8 $ (95.8 ) $ 1,305.3 Net income — — — — — 56.1 — 56.1 Activity related to stock-based compensation — — (3.8 ) (0.2 ) 16.0 — — 12.2 Shares purchased under share repurchase program — — — 0.3 (22.9 ) — — (22.9 ) Dividends declared ($0.14 per share) — — — — — (20.9 ) — (20.9 ) Other comprehensive loss, net of tax — — — — — — (47.9 ) (47.9 ) Balance, June 30, 2018 75.3 $ 18.8 $ 304.7 1.8 $ (155.9 ) $ 1,258.0 $ (143.7 ) $ 1,281.9 Net income — — — — — 55.2 — 55.2 Activity related to stock-based compensation — — (21.9 ) (0.6 ) 47.2 — — 25.3 Dividends declared ($0.15 per share) — — — — — (0.5 ) — (0.5 ) Other comprehensive loss, net of tax — — — — — — (10.1 ) (10.1 ) Balance, September 30, 2018 75.3 $ 18.8 $ 282.8 1.2 $ (108.7 ) $ 1,312.7 $ (153.8 ) $ 1,351.8

Benefit Plans (Tables)

Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2019
Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Abstract]
Schedule of Components of Net Periodic Benefit Cost	The components of net periodic benefit cost for the three months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 0.4 $ 2.6 $ — $ — $ 0.4 $ 2.6 Interest cost 1.9 2.3 0.1 0.1 2.0 2.4 Expected return on assets (3.1 ) (3.9 ) — — (3.1 ) (3.9 ) Amortization of prior service credit 0.1 (0.3 ) (0.2 ) (0.2 ) (0.1 ) (0.5 ) Recognized actuarial losses (gains) 0.5 0.9 (0.7 ) (0.7 ) (0.2 ) 0.2 Settlements 2.7 — — — 2.7 — Net periodic benefit cost $ 2.5 $ 1.6 $ (0.8 ) $ (0.8 ) $ 1.7 $ 0.8 Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 U.S. plans $ 2.0 $ 1.0 $ (0.8 ) $ (0.8 ) $ 1.2 $ 0.2 International plans 0.5 0.6 — — 0.5 0.6 Net periodic benefit cost $ 2.5 $ 1.6 $ (0.8 ) $ (0.8 ) $ 1.7 $ 0.8 The components of net periodic benefit cost for the nine months ended September 30 were as follows: Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 Service cost $ 1.1 $ 8.1 $ — $ — $ 1.1 $ 8.1 Interest cost 6.8 7.0 0.2 0.2 7.0 7.2 Expected return on assets (8.9 ) (11.7 ) — — (8.9 ) (11.7 ) Amortization of prior service credit 0.1 (1.1 ) (0.5 ) (0.5 ) (0.4 ) (1.6 ) Recognized actuarial losses (gains) 1.6 2.8 (1.8 ) (1.8 ) (0.2 ) 1.0 Settlements 2.7 — — — 2.7 — Net periodic benefit cost $ 3.4 $ 5.1 $ (2.1 ) $ (2.1 ) $ 1.3 $ 3.0 Pension benefits Other retirement benefits Total ($ in millions) 2019 2018 2019 2018 2019 2018 U.S. plans $ 1.9 $ 3.5 $ (2.1 ) $ (2.1 ) $ (0.2 ) $ 1.4 International plans 1.5 1.6 — — 1.5 1.6 Net periodic benefit cost $ 3.4 $ 5.1 $ (2.1 ) $ (2.1 ) $ 1.3 $ 3.0

Other Expense (Tables)

Other Expense (Tables)	9 Months Ended
	Sep. 30, 2019
Other Income and Expenses [Abstract]
Schedule of Other Expense	Other expense (income) consists of: Three Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Restructuring and related charges: Severance and post-employment benefits $ 0.6 $ 0.1 $ 2.2 $ 3.4 Asset-related charges 0.1 0.4 0.1 0.8 Other charges 1.1 0.7 1.5 2.5 Total restructuring and related charges 1.8 1.2 3.8 6.7 Argentina currency devaluation 1.0 1.1 1.0 1.1 Development and licensing income (0.2 ) (0.2 ) (0.6 ) (0.6 ) Contingent consideration 0.1 0.2 0.4 0.8 Other items 3.7 (2.5 ) (3.0 ) (4.0 ) Total other expense (income) $ 6.4 $ (0.2 ) $ 1.6 $ 4.0
Schedule of Restructuring Reserve	The following table presents activity related to our restructuring obligations related to our 2018 restructuring plan: ($ in millions) Severance and benefits Asset-related charges Other charges Total Balance, December 31, 2018 $ 2.3 $ — $ — $ 2.3 Charges 2.2 0.1 1.5 3.8 Cash payments (2.0 ) — — (2.0 ) Non-cash asset write-downs — (0.1 ) (1.5 ) (1.6 ) Balance, September 30, 2019 $ 2.5 $ — $ — $ 2.5

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2019
Segment Reporting [Abstract]
Segment Information	The following table presents information about our reportable segments, reconciled to consolidated totals: Three Months Ended Nine Months Ended ($ in millions) 2019 2018 2019 2018 Net sales: Proprietary Products $ 345.2 $ 325.2 $ 1,045.9 $ 997.4 Contract-Manufactured Products 111.1 106.7 323.6 297.7 Intersegment sales elimination (0.2 ) (0.2 ) (0.2 ) (0.2 ) Consolidated net sales $ 456.1 $ 431.7 $ 1,369.3 $ 1,294.9 Operating profit (loss): Proprietary Products $ 72.9 $ 68.2 $ 238.7 $ 202.7 Contract-Manufactured Products 11.6 11.2 33.5 29.7 Corporate (14.4 ) (16.3 ) (48.9 ) (50.1 ) Other unallocated items (2.8 ) (2.3 ) (4.8 ) (7.8 ) Total operating profit $ 67.3 $ 60.8 $ 218.5 $ 174.5 Interest expense 2.1 2.0 6.4 6.1 Interest income (1.0 ) (0.5 ) (2.5 ) (1.4 ) Other nonoperating expense (income) 1.3 (1.8 ) 0.2 (5.1 ) Income before income taxes $ 64.9 $ 61.1 $ 214.4 $ 174.9

Summary of Significant Accoun_3

Summary of Significant Accounting Policies Business Combinations (Details) $ in Millions	Apr. 01, 2019USD ($)
Business Combinations [Abstract]
Business acquisition, transaction costs	$ 18.9
Business combination, recognized inventory	4.5
Business combination, recognized property, plant, and equipment	0.6
Business combination, recognized goodwill	2.6
Business combination, recognized intangible assets	$ 11.2

Revenue Recognition (Details)

Revenue Recognition (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation of Revenue [Line Items]
Percentage of net sales	100.00%	100.00%	100.00%	100.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | High-Value Components [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	42.00%	41.00%	43.00%	42.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Standard Packaging [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	28.00%	31.00%	29.00%	32.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Delivery Devices [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	6.00%	4.00%	4.00%	3.00%
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Contract-Manufactured Products [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	24.00%	24.00%	24.00%	23.00%
Biologics [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	26.00%	21.00%	25.00%	21.00%
Generics [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	20.00%	21.00%	20.00%	21.00%
Pharma Customers [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	30.00%	34.00%	31.00%	35.00%
Contract-Manufactured Products [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	24.00%	24.00%	24.00%	23.00%
Americas [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	48.00%	51.00%	48.00%	48.00%
Europe, Middle East, Africa [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	44.00%	41.00%	44.00%	44.00%
Asia Pacific [Member] | Revenue Benchmark [Member] | Geographic Concentration Risk [Member]
Disaggregation of Revenue [Line Items]
Percentage of net sales	8.00%	8.00%	8.00%	8.00%

Contracts and Liabilities (Deta

Contracts and Liabilities (Details) - USD ($) $ in Millions	Jan. 01, 2019	Sep. 30, 2019
Contract assets, December 31, 2018	$ 9.1	$ 9.1
Contract assets, September 30, 2019		9.4
Change in contract assets - increase (decrease)		0.3
Deferred income, December 31, 2018	(33.4)	(33.4)
Deferred income, September 30, 2019		(30.9)
Change in deferred income - decrease (increase)		2.5
Revenue recognized that was included in the deferred income balance	$ 18	79.3
Other adjustments		2.7
Customer advance cash payments		79.5
SmartDose [Member]
Deferred income, September 30, 2019		(5.9)
Deferred income, current		0.9
Deferred income, noncurrent		$ 5

Revenue Supply Chain Financing

Revenue Supply Chain Financing (Details) $ in Millions	Sep. 30, 2019USD ($)
Supply Chain Financing [Abstract]
Sales of certain accounts receivable	$ 7.9

Revenue Voluntary Recall (Detai

Revenue Voluntary Recall (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Dec. 31, 2018
Revenue from Contract with Customer [Abstract]
Provision for sales returns	$ (0.9)	$ (4.9)	$ (11.3)

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Earnings Per Share [Abstract]
Net income	$ 56.3	$ 66.1	$ 55.4	$ 55.2	$ 56.1	$ 43.6	$ 177.8	$ 154.9
Weighted average common shares outstanding (in shares)	74,000,000			73,900,000			73,900,000	73,900,000
Dilutive effect of equity awards, based on the treasury stock method (in shares)	1,500,000			1,800,000			1,400,000	1,500,000
Weighted average shares assuming dilution (in shares)	75,500,000			75,700,000			75,300,000	75,400,000
Antidilutive options excluded from computation of diluted net income per share (in shares)	100,000			100,000			300,000	400,000
Stock repurchase program, shares authorized									800,000
Stock repurchase program, shares purchased							800,000
Stock purchase program, cost of shares purchased			$ 83.1		$ 22.9	$ 47.9	$ 83.1
Stock repurchase program, average price per share							$ 103.89

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 99.2	$ 90.4
Work in process	38.3	42.2
Finished goods	92.9	81.9
Total inventories	$ 230.4	$ 214.5

Leases Adoption of ASC 842 (Det

Leases Adoption of ASC 842 (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2019	Jan. 01, 2019	Dec. 31, 2018
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total lease liabilities	$ 73.3
Operating lease right-of-use assets	$ 71.3		$ 0
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Total lease liabilities		$ 73.1
Operating lease right-of-use assets		$ 71
Maximum [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating leases, term of contracts	12 months
Operating leases, option to extend	5 years

Leases Lease Cost (Details)

Leases Lease Cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Lease, Cost [Abstract]
Operating lease cost	$ 3.4		$ 9.7
Short-term lease cost	0.1		0.5
Variable lease cost	0.8		2.3
Total lease cost	$ 4.3	$ 3.3	$ 12.5	$ 10.4

Leases Lease Cash Flow and Supp

Leases Lease Cash Flow and Supplemental Information (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Lease Cash Flow and Supplemental Information [Abstract]
Operating lease payments	$ 3.2	$ 9.4
Right-of-use assets obtained in exchange for new operating lease liabilities	$ 0.3	$ 8.4

Leases Lease Weighted Average (

Leases Lease Weighted Average (Details)	Sep. 30, 2019
Lease Cash Flow and Supplemental Information [Abstract]
Weighted average remaining lease term	11 years 9 months 18 days
Weighted average discount rate	3.76%

Leases Maturities of Operating

Leases Maturities of Operating Lease Liabilities (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Leases [Abstract]
2019 (remaining three months)	$ 3.4
2020	12
2021	10.2
2022	8.3
2023	7.7
Thereafter	48.1
Operating leases liabilities payments due	89.7
Less: imputed lease interest	16.4
Total lease liabilities	$ 73.3
2019		$ 13
2020		10.5
2021		7.8
2022		6.9
2023		5.5
Thereafter		37.8
Total		$ 81.5

Affiliated Companies (Details)

Affiliated Companies (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Schedule of Equity Method Investments [Line Items]
Purchases and royalty payments made to affiliates	$ 33	$ 16.3	$ 85.2	$ 64
Amount due and payable to affiliates	24.3		24.3		$ 12.9
Sales to affiliates	2.2	$ 3	6.9	$ 8
Amount receivable from affiliates	1.4		1.4		1.6
Carrying amount, equity-method investments	84		84		77.8
Carrying amount, cost-method investments	$ 13.4		$ 13.4		$ 13.4

Long-term Debt (Details)

Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Long-term debt, gross	$ 195.6	$ 196.7
Long-term debt	195.1	196.1
Unamortized debt issuance costs	0.5	0.6
Current portion of long-term debt	0	0.1
Long-term debt, excluding current portion	195.1	196
Notes payable, Due 2019 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	0	0.1
Revolving credit facility, Due 2020 [Member]
Debt Instrument [Line Items]
Long-term debt, gross	$ 0	$ 28.6
Revolving credit facility, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, stated interest rate	0.875%
Long-term debt, gross	$ 27.6
Series A Notes, Due 2022 [Member]
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.67%	3.67%
Long-term debt, gross	$ 42	$ 42
Series B Notes, Due 2024 [Member]
Debt Instrument [Line Items]
Debt instrument, stated interest rate	3.82%	3.82%
Long-term debt, gross	$ 53	$ 53
Series C Notes, Due 2027 [Member]
Debt Instrument [Line Items]
Debt instrument, stated interest rate	4.02%	4.02%
Long-term debt, gross	$ 73	$ 73

Credit Facility (Details)

Credit Facility (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Line of Credit Facility [Line Items]
Unamortized debt issuance costs	$ 500,000	$ 600,000
Revolving credit facility, Due 2024 [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, current borrowing capacity	300,000,000
Line of Credit Facility, additional borrowing capacity	350,000,000
Credit available for the issuance of letters of credit	30,000,000
Line of Credit Facility, noncurrent	27,600,000
Line of Credit Facility outstanding borrowings, Yen	4,600,000
Line of Credit Facility outstanding borrowings, Euro	23,000,000
Line of Credit Facility, unused commitment level	269,900,000
Debt issuance costs	$ 1,100,000	$ 600,000
Revolving credit facility, Due 2024 [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	1.00%
Revolving credit facility, Due 2024 [Member] | Fed Funds Effective Rate Overnight Index Swap Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	50.00%
Revolving credit facility, Due 2024 [Member] | Letter of Credit [Member]
Line of Credit Facility [Line Items]
Long-term Line of Credit	$ 2,500,000
Revolving credit facility, Due 2024 [Member] | Foreign Line of Credit [Member]
Line of Credit Facility [Line Items]
Credit facility is available for swing-line loans	20,000,000
Revolving credit facility, Due 2024 [Member] | Domestic Line of Credit [Member]
Line of Credit Facility [Line Items]
Credit facility is available for swing-line loans	$ 30,000,000
Maximum [Member] | Revolving credit facility, Due 2024 [Member]
Line of Credit Facility [Line Items]
Ratio of debt to EBITDA	4
Maximum [Member] | Revolving credit facility, Due 2024 [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	137.50%
Maximum [Member] | Revolving credit facility, Due 2024 [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	37.50%
Minimum [Member] | Revolving credit facility, Due 2024 [Member]
Line of Credit Facility [Line Items]
Ratio of debt to EBITDA	3.5
Minimum [Member] | Revolving credit facility, Due 2024 [Member] | London Interbank Offered Rate (LIBOR) [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	87.50%
Minimum [Member] | Revolving credit facility, Due 2024 [Member] | Base Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, stated interest rate	0.00%

Derivative Financial Instrume_3

Derivative Financial Instruments (Textuals) (Details) € in Millions, ¥ in Millions, $ in Millions, $ in Millions	9 Months Ended
	Sep. 30, 2019EUR (€)MBbls$ / bbl	Sep. 30, 2019JPY (¥)	Sep. 30, 2019USD ($)	Sep. 30, 2019SGD ($)MBbls$ / bbl	Sep. 30, 2019JPY (¥)MBbls$ / bbl	Sep. 30, 2019USD ($)MBbls$ / bbl	Dec. 31, 2018EUR (€)	Dec. 31, 2018SGD ($)	Dec. 31, 2018USD ($)	Nov. 22, 2017MBbls
Debt EUR Denominated [Member]
Derivative [Line Items]
Notional amount, nonderivative instruments	€ 21		$ 23
Cumulative foreign currency translation loss						$ 0.6
Cumulative foreign currency translation loss, net of tax						0.5
Debt Yen Denominated [Member]
Derivative [Line Items]
Notional amount, nonderivative instruments		¥ 500	$ 4.6
Cumulative foreign currency translation loss						0.5
Cumulative foreign currency translation loss, net of tax						$ 0.4
Options Held [Member]
Derivative [Line Items]
Derivative, Nonmonetary Notional Amount | MBbls	107,909			107,909	107,909	107,909				301,326
Derivative, Average Price Risk Option Strike Price | $ / bbl	71.15			71.15	71.15	71.15
Euro Member Countries, Euro | Forward Contracts [Member]
Derivative [Line Items]
Derivative, Notional Amount | €							€ 10
Singapore, Dollars | Forward Contracts [Member]
Derivative [Line Items]
Derivative, Notional Amount				$ 601.5				$ 601.5
United States of America, Dollars | Forward Contracts [Member]
Derivative [Line Items]
Derivative, Notional Amount						$ 13.4			$ 13.4
Long [Member] | Designated as Hedging Instrument [Member] | Singapore, Dollars | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount				$ 31.9
Long [Member] | Designated as Hedging Instrument [Member] | United States of America, Dollars | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount						39.3
Long [Member] | Designated as Hedging Instrument [Member] | Japan, Yen | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount | ¥					¥ 5,921.1
Short [Member] | Designated as Hedging Instrument [Member] | Singapore, Dollars | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount	€ 4.3					18.7
Short [Member] | Designated as Hedging Instrument [Member] | United States of America, Dollars | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount	34.2					0
Short [Member] | Designated as Hedging Instrument [Member] | Japan, Yen | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Notional Amount	€ 20.2					$ 31.8

Effects of Derivative Instrumen

Effects of Derivative Instruments on OCI and Earnings (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Derivative Instruments, Gain (Loss) [Line Items]
Document Period End Date			Sep. 30, 2019
Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	$ (0.6)		$ 3.9
Derivative, Gain (Loss) on Derivative, Net	4.3	$ (2)	(5)	$ (3.4)
Amount of (gain) loss reclassified from accumulated OCI into income	2.9		(3.3)
Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	1.3	(0.4)	2.1	1.1
Amount of (gain) loss reclassified from accumulated OCI into income	(0.4)	0	(1)	1.4
Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	0.1	0	0.3	(0.5)
Net Investment Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0.7	0.2	0.5	0.7
Amount of (gain) loss reclassified from accumulated OCI into income	0	0	0	0
Foreign Currency Hedge Contracts [Member] | Net sales [Member] | Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0.7	0.1	1	0.2
Amount of (gain) loss reclassified from accumulated OCI into income	(0.3)	0	(0.7)	0.8
Foreign Currency Hedge Contracts [Member] | Cost of goods and services sold [Member] | Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0.6	(0.5)	1.1	0.9
Amount of (gain) loss reclassified from accumulated OCI into income	(0.2)	(0.1)	(0.5)	0.4
Foreign Currency Hedge Contracts [Member] | Other expense [Member] | Fair Value Hedging [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	(0.6)		3.9
Derivative, Gain (Loss) on Derivative, Net	4.3	(2)	(5)	(3.4)
Amount of (gain) loss reclassified from accumulated OCI into income	2.9		(3.3)
Foreign Currency Hedge Contracts [Member] | Cost of goods and services sold [Member] | Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net	0.1	0	0.3	(0.5)
Forward Treasury Locks [Member] | Interest expense [Member] | Cash Flow Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0	0	0	0
Amount of (gain) loss reclassified from accumulated OCI into income	0.1	0.1	0.2	0.2
Foreign Currency - Denominated Debt [Member] | Other expense [Member] | Net Investment Hedges [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, before Tax	0.7	0.2	0.5	0.7
Amount of (gain) loss reclassified from accumulated OCI into income	$ 0	$ 0	$ 0	$ 0

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Assets:
Deferred compensation assets	$ 9.9	$ 8.7
Foreign currency contracts	13.2	6.5
Commodity call options	0.1
Total assets at fair value	23.2	15.2
Liabilities:
Contingent consideration	1.8	1.7
Deferred compensation liabilities	11.4	9.8
Foreign currency contracts	0.2	0.2
Total liabilities at fair value	13.4	11.7
Level 1 [Member]
Assets:
Deferred compensation assets	9.9	8.7
Total assets at fair value	9.9	8.7
Liabilities:
Deferred compensation liabilities	11.4	9.8
Total liabilities at fair value	11.4	9.8
Level 2 [Member]
Assets:
Foreign currency contracts	13.2	6.5
Commodity call options	0.1
Total assets at fair value	13.3	6.5
Liabilities:
Foreign currency contracts	0.2	0.2
Total liabilities at fair value	0.2	0.2
Level 3 [Member]
Liabilities:
Contingent consideration	1.8	1.7
Total liabilities at fair value	$ 1.8	$ 1.7

Fair Value Measurements Level 3

Fair Value Measurements Level 3 (Details) - USD ($) $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Level 3 Fair Value Measurements [Roll Forward]
Balance, beginning of period	$ 1.7	$ 4.9
Increase (decrease) in fair value recorded in earnings	0.4	(2.6)
Payments	(0.3)	(0.6)
Balance, end of period	$ 1.8	$ 1.7

Fair Value Measurements Other F

Fair Value Measurements Other Financial Instruments (Details) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Other Financial Instruments [Abstract]
Long-term debt, fair value	$ 204.4	$ 192.6
Long-term debt	$ 195.1	$ 196

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss Components (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning			$ (154.2)				$ (154.2)
Other comprehensive income (loss) before reclassifications							(13.5)
Amounts reclassified out							(2.7)
Other comprehensive loss, net of tax	$ (18.2)	$ 1.2	0.8	$ (10.1)	$ (47.9)	$ 21.5	(16.2)	$ (36.5)
Balance, ending	(170.4)						(170.4)
Gains (Losses) on Cash Flow Hedges [Member]
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning			(0.4)				(0.4)
Other comprehensive income (loss) before reclassifications							6
Amounts reclassified out							(4.3)
Other comprehensive loss, net of tax							1.7
Balance, ending	1.3						1.3
Unrealized Gains on Investment Securities [Member]
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning			0.4				0.4
Other comprehensive income (loss) before reclassifications							0
Amounts reclassified out							0
Other comprehensive loss, net of tax							0
Balance, ending	0.4						0.4
Defined Benefit Pension and Other Postretirement Plans [Member]
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning			(40.4)				(40.4)
Other comprehensive income (loss) before reclassifications							0.6
Amounts reclassified out							1.6
Other comprehensive loss, net of tax							2.2
Balance, ending	(38.2)						(38.2)
Foreign Currency Translation [Member]
Changes in the Components of Accumulated Other Comprehensive Loss, Net of Tax [Roll Forward]
Balance, beginning			$ (113.8)				(113.8)
Other comprehensive income (loss) before reclassifications							(20.1)
Amounts reclassified out							0
Other comprehensive loss, net of tax							(20.1)
Balance, ending	$ (133.9)						$ (133.9)

Accumulated Other Comprehensi_4

Accumulated Other Comprehensive Loss Reclassifications (Details) - USD ($) $ in Millions		3 Months Ended						9 Months Ended
		Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales		$ 456.1			$ 431.7			$ 1,369.3	$ 1,294.9
Cost of goods and services sold		(308.3)			(296.1)			(916.8)	(882.7)
Interest expense		(2.1)			(2)			(6.4)	(6.1)
Prior service cost		0.1			0.5			0.4	1.6
Actuarial losses		0.2			(0.2)			0.2	(1)
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement		(2.7)			0			(2.7)	0
Income before income taxes		64.9			61.1			214.4	174.9
Tax expense (benefit)		(10.9)			(8)			(42.5)	(26.5)
Net income		56.3	$ 66.1	$ 55.4	55.2	$ 56.1	$ 43.6	177.8	154.9
Reclassification out of Accumulated Other Comprehensive Loss [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net income		(4.3)			0.3			2.7	(0.9)
Reclassification out of Accumulated Other Comprehensive Loss [Member] | Gains (Losses) on Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Income before income taxes		(3.8)			0			6.3	(1.8)
Tax expense (benefit)		1.3			0			(2)	0.4
Net income		(2.5)			0			4.3	(1.4)
Reclassification out of Accumulated Other Comprehensive Loss [Member] | Amortization of Defined Benefit Pension and Other Postretirement Plans [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Prior service cost	[1]	0.1			0.5			0.4	1.6
Actuarial losses	[1]	0.2			(0.2)			0.2	(1)
Income before income taxes		(2.4)			0.3			(2.1)	0.6
Tax expense (benefit)		0.6			0			0.5	(0.1)
Net income		(1.8)			0.3			(1.6)	0.5
Foreign Currency Contract [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Gains (Losses) on Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Net sales		0.3			0.1			0.8	(0.8)
Cost of goods and services sold		0.3			0			0.8	(0.7)
Interest Rate Swap Contracts [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Gains (Losses) on Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Interest expense		(4.3)			0			5	0
Forward Treasury Locks [Member] | Reclassification out of Accumulated Other Comprehensive Loss [Member] | Gains (Losses) on Cash Flow Hedges [Member]
Reclassification out of Accumulated Other Comprehensive Loss [Line Items]
Interest expense		$ (0.1)			$ (0.1)			$ (0.3)	$ (0.3)
[1]	These components are included in the computation of net periodic benefit cost. Please refer to Note 14, Benefit Plans , for additional details.

Supplemental Equity Information

Supplemental Equity Information (Details) - $ / shares	3 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018
Equity [Abstract]
Dividends declared per share	$ 0.16	$ 0.15	$ 0.15	$ 0.15	$ 0.14	$ 0.14

Change in Shareholders' Equity

Change in Shareholders' Equity (Details) - USD ($) $ in Millions	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 1,445.1	$ 1,369.5	$ 1,396.3	$ 1,281.9	$ 1,305.3	$ 1,279.9	$ 1,396.3	$ 1,279.9
Cumulative effect of new accounting principle in period of adoption						11.4
Net income	56.3	66.1	55.4	55.2	56.1	43.6	$ 177.8	154.9
Activity related to stock-based compensation	16.3	19.7	10.7	25.3	12.2	7.2
Share purchased under share repurchase program (in shares)							800,000
Shares purchased under share repurchase program			(83.1)		(22.9)	(47.9)	$ (83.1)
Dividends declared	(11.9)	(11.4)	(10.6)	(0.5)	(20.9)	(10.4)
Other comprehensive income, net of tax	(18.2)	1.2	0.8	(10.1)	(47.9)	21.5	(16.2)	(36.5)
Balance	1,487.6	1,445.1	1,369.5	1,351.8	1,281.9	1,305.3	1,487.6	1,351.8
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,200,000	75,300,000	75,200,000
Shares issued under stock plans (in shares)	0	0	0		0	100,000
Activity related to stock-based compensation	$ 0	$ 0	$ 0		$ 0	$ 0
Balance	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8	$ 18.8
Balance (in shares)	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000	75,300,000
Additional Paid-in Capital [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 273.4	$ 278.5	$ 282	$ 304.7	$ 308.5	$ 309.3	$ 282	$ 309.3
Activity related to stock-based compensation	(4.9)	(5.1)	(3.5)	(21.9)	(3.8)	(0.8)
Balance	268.5	273.4	278.5	282.8	304.7	308.5	268.5	282.8
Treasury Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ (147.8)	$ (172.6)	$ (103.7)	$ (155.9)	$ (149)	$ (109.1)	$ (103.7)	$ (109.1)
Balance (in shares)	1,600,000	1,800,000	1,200,000	1,800,000	1,700,000	1,300,000	1,200,000	1,300,000
Shares issued under stock plans (in shares)	(300,000)	(200,000)	(200,000)	(600,000)	(200,000)	(100,000)
Activity related to stock-based compensation	$ 21.2	$ 24.8	$ 14.2	$ 47.2	$ 16	$ 8
Share purchased under share repurchase program (in shares)			800,000		300,000	500,000
Shares purchased under share repurchase program			$ (83.1)		$ (22.9)	$ (47.9)
Balance	$ (126.6)	$ (147.8)	$ (172.6)	$ (108.7)	$ (155.9)	$ (149)	$ (126.6)	$ (108.7)
Balance (in shares)	1,300,000	1,600,000	1,800,000	1,200,000	1,800,000	1,700,000	1,300,000	1,200,000
Retained Earnings [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	$ 1,452.9	$ 1,398.2	$ 1,353.4	$ 1,258	$ 1,222.8	$ 1,178.2	$ 1,353.4	$ 1,178.2
Cumulative effect of new accounting principle in period of adoption						11.4
Net income	56.3	66.1	55.4	55.2	56.1	43.6
Dividends declared	11.9	11.4	10.6	(0.5)	(20.9)	(10.4)
Balance	1,497.3	1,452.9	1,398.2	1,312.7	1,258	1,222.8	1,497.3	1,312.7
AOCI Attributable to Parent [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance	(152.2)	(153.4)	(154.2)	(143.7)	(95.8)	(117.3)	(154.2)	(117.3)
Other comprehensive income, net of tax	(18.2)	1.2	0.8	(10.1)	(47.9)	21.5
Balance	$ (170.4)	$ (152.2)	$ (153.4)	$ (153.8)	$ (143.7)	$ (95.8)	$ (170.4)	$ (153.8)

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for issuance under the 2016 Plan (in shares)	3,110,708		3,110,708
Stock options, granted (in shares)			345,400
Stock options, weighted average exercise price (in dollars per share)			$ 102.59
Stock options, weighted average grant date fair value (in dollars per share)			$ 24.53
Risk-free interest rate (in hundredths)			2.30%
Expected life (in years)			5 years 7 months 6 days
Stock volatility (in hundredths)			22.50%
Dividend yield (in hundredths)			0.70%
Stock-based compensation expense	$ 5.4	$ 5.3	$ 18.8	$ 14.7
Performance Share Unit (PSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			82,646
Grant date fair value (in dollars per share)			$ 102.59
PSU payout, minimum (in hundredths)	0.00%		0.00%
PSU payout, maximum (in hundredths)	200.00%		200.00%
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			11,631
Grant date fair value (in dollars per share)			$ 112.49

Benefit Plans (Details)

Benefit Plans (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	$ 0.4	$ 2.6	$ 1.1	$ 8.1
Interest cost	2	2.4	7	7.2
Expected return on assets	(3.1)	(3.9)	(8.9)	(11.7)
Amortization of prior service credit	(0.1)	(0.5)	(0.4)	(1.6)
Recognized actuarial losses (gains)	(0.2)	0.2	(0.2)	1
Settlements	2.7	0	2.7	0
Net periodic benefit cost	1.7	0.8	1.3	3
Contributions by employer	2.6		2.6
UNITED STATES
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	1.2	0.2	(0.2)	1.4
Foreign Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0.5	0.6	1.5	1.6
Pension Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	0.4	2.6	1.1	8.1
Interest cost	1.9	2.3	6.8	7
Expected return on assets	(3.1)	(3.9)	(8.9)	(11.7)
Amortization of prior service credit	0.1	(0.3)	0.1	(1.1)
Recognized actuarial losses (gains)	0.5	0.9	1.6	2.8
Settlements	2.7	0	2.7
Net periodic benefit cost	2.5	1.6	3.4	5.1
Pension Benefits [Member] | UNITED STATES
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	2	1	1.9	3.5
Pension Benefits [Member] | Foreign Plan [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	0.5	0.6	1.5	1.6
Other Retirement Benefits [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Service cost	0	0	0	0
Interest cost	0.1	0.1	0.2	0.2
Amortization of prior service credit	(0.2)	(0.2)	(0.5)	(0.5)
Recognized actuarial losses (gains)	(0.7)	(0.7)	(1.8)	(1.8)
Net periodic benefit cost	(0.8)	(0.8)	(2.1)	(2.1)
Other Retirement Benefits [Member] | UNITED STATES
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Net periodic benefit cost	(0.8)	$ (0.8)	(2.1)	$ (2.1)
Other Nonoperating Income (Expense) [Member]
Defined Benefit Plans and Other Postretirement Benefit Plans [Line Items]
Settlements	$ 2.7		$ 2.7

Other Expense (Details)

Other Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other Income and Expenses [Abstract]
Restructuring Charges	$ 1.8	$ 1.2	$ 3.8	$ 6.7
Argentina currency devaluation	1	1.1	1	1.1
Development and licensing income	(0.2)	(0.2)	(0.6)	(0.6)
Contingent consideration	0.1	0.2	0.4	0.8
Other items	3.7	(2.5)	(3)	(4)
Total other expense (income)	$ 6.4	$ (0.2)	$ 1.6	$ 4

Other Expense Items (Details)

Other Expense Items (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Other Income and Expenses [Abstract]
Restructuring Charges	$ 1.8	$ 1.2	$ 3.8	$ 6.7
Increase (decrease) of other items	6.2		$ 1
Foreign exchange transaction (gain) loss	$ 5.1	$ (2.7)

Other Expense Restructuring and

Other Expense Restructuring and Related Charges (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Deferred income	$ 30.9		$ 30.9			$ 33.4
Argentina currency devaluation	1	$ 1.1	1	$ 1.1
Payments to acquire property, plant, and equipment			88.8	74.7
Restructuring and related charges	1.8	1.2	3.8	6.7
Restructuring Reserve [Roll Forward]
Non-cash asset-write-downs			(1.6)	(0.8)
Severance and benefits [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018			2.3
Charges			2.2
Cash payments			(2)
Non-cash asset-write-downs			0
Balance, September 30, 2019	2.5		2.5
Asset-related charges [Member]
Restructuring Reserve [Roll Forward]
Cash payments			0
Other charges [Member]
Restructuring Reserve [Roll Forward]
Cash payments			0
2018 Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, cumulative cost incurred	12.6		12.6
Severance charges	0.6	0.1	2.2	3.4
Asset impairment charges, equipment	0.1	0.4	0.1	0.8
Other charges	1.1	0.7	1.5	2.5
Restructuring and related charges	1.8		3.8
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018			2.3
Charges		$ 1.2	3.8	$ 6.7
Cash payments			(2)
Non-cash asset-write-downs			(1.6)
Balance, September 30, 2019	2.5		2.5
2018 Restructuring Plan [Member] | Asset-related charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018			0
Charges			0.1
Non-cash asset-write-downs			(0.1)
Balance, September 30, 2019	0		0
2018 Restructuring Plan [Member] | Other charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2018			0
Charges			1.5
Non-cash asset-write-downs			(1.5)
Balance, September 30, 2019	0		0
2018 Restructuring Plan [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and related cost, expected cost					$ 16
2016 Restructuring Plan [Member]
Restructuring Reserve [Roll Forward]
Balance, September 30, 2019	$ 0.2		$ 0.2

Other Expense Other (Income) De

Other Expense Other (Income) Development and Licensing Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Jun. 30, 2013
Development and licensing income [Line Items]
Development and licensing income	$ 0.2	$ 0.2	$ 0.6	$ 0.6
Deferred income	30.9		30.9		$ 33.4
SmartDose [Member]
Development and licensing income [Line Items]
Development and licensing income	$ 0.2		$ 0.6
Deferred income						$ 20

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Income Tax Disclosure [Abstract]
Tax expense (benefit)	$ 10.9	$ 8	$ 42.5	$ 26.5
Effective income tax rate	16.80%	13.10%	19.80%	15.10%
Other Income Tax Expense (Benefit), Continuing Operations	$ 1		$ 1
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Tax Cuts and Jobs Act of 2017, provisional income tax expense		$ (0.4)		$ 4.1

Segment Information (Details)

Segment Information (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019USD ($)	Sep. 30, 2018USD ($)	Sep. 30, 2019USD ($)segment	Sep. 30, 2018USD ($)
Segment Reporting [Abstract]
Number of reportable segments | segment			2
Restructuring and related charges	$ 1.8	$ 1.2	$ 3.8	$ 6.7
Argentina currency devaluation	1	1.1	1	1.1
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	456.1	431.7	1,369.3	1,294.9
Total operating (loss) profit	67.3	60.8	218.5	174.5
Interest expense	2.1	2	6.4	6.1
Interest income	(1)	(0.5)	(2.5)	(1.4)
Other nonoperating income	1.3	(1.8)	0.2	(5.1)
Income before income taxes	64.9	61.1	214.4	174.9
Proprietary Products [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	345.2	325.2	1,045.9	997.4
Total operating (loss) profit	72.9	68.2	238.7	202.7
Contract-Manufactured Products [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	111.1	106.7	323.6	297.7
Total operating (loss) profit	11.6	11.2	33.5	29.7
Intersegment sales elimination [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Net sales	(0.2)	(0.2)	(0.2)	(0.2)
Corporate [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating (loss) profit	(14.4)	(16.3)	(48.9)	(50.1)
Other unallocated items [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Total operating (loss) profit	$ (2.8)	$ (2.3)	$ (4.8)	$ (7.8)

Subsequent Event (Details)

Subsequent Event (Details)	Oct. 15, 2019
Subsequent Event [Line Items]
Equity Method Investment, Ownership Percentage	49.00%